US20160340435A1 - Molecular constructs for treating central nervous system diseases - Google Patents
Molecular constructs for treating central nervous system diseases Download PDFInfo
- Publication number
- US20160340435A1 US20160340435A1 US15/159,862 US201615159862A US2016340435A1 US 20160340435 A1 US20160340435 A1 US 20160340435A1 US 201615159862 A US201615159862 A US 201615159862A US 2016340435 A1 US2016340435 A1 US 2016340435A1
- Authority
- US
- United States
- Prior art keywords
- pair
- scfv
- targeting
- effector
- elements
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000015114 central nervous system disease Diseases 0.000 title claims description 13
- 239000012636 effector Substances 0.000 claims abstract description 85
- 230000008685 targeting Effects 0.000 claims abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 37
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 40
- 230000027455 binding Effects 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 210000003169 central nervous system Anatomy 0.000 claims description 25
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 22
- 108010041012 Integrin alpha4 Proteins 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 16
- 229960004461 interferon beta-1a Drugs 0.000 claims description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
- 201000006417 multiple sclerosis Diseases 0.000 claims description 11
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims description 8
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 8
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims description 2
- 102000047882 human INSR Human genes 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 51
- 239000003814 drug Substances 0.000 description 29
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 25
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 230000001225 therapeutic effect Effects 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 24
- 239000002158 endotoxin Substances 0.000 description 23
- 230000008499 blood brain barrier function Effects 0.000 description 22
- 210000001218 blood-brain barrier Anatomy 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108020001507 fusion proteins Proteins 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108091006020 Fc-tagged proteins Proteins 0.000 description 14
- 229960000556 fingolimod Drugs 0.000 description 14
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 108010033576 Transferrin Receptors Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 8
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 241000193738 Bacillus anthracis Species 0.000 description 4
- 108010077805 Bacterial Proteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- LRFKWQGGENFBFO-UHFFFAOYSA-N fingolimod phosphate Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)COP(O)(O)=O)C=C1 LRFKWQGGENFBFO-UHFFFAOYSA-N 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 3
- 241000193163 Clostridioides difficile Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 3
- 101710082439 Hemagglutinin A Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229960005027 natalizumab Drugs 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- GRPUBDDSELRCNH-UHFFFAOYSA-N C.C.C.C Chemical compound C.C.C.C GRPUBDDSELRCNH-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229960004910 raxibacumab Drugs 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N C.C Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 229940126609 CR6261 Drugs 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 101710198480 Clumping factor A Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 102000014748 Junctional Adhesion Molecules Human genes 0.000 description 1
- 108010064064 Junctional Adhesion Molecules Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010056430 Staphylococcal sepsis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229950004283 actoxumab Drugs 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950008995 aducanumab Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 229950008086 bezlotoxumab Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229950001954 crenezumab Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229950011037 diridavumab Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950011109 edobacomab Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229950005562 exbivirumab Drugs 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 229950004409 firivumab Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950002508 gantenerumab Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229950005173 libivirumab Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003419 obiltoxaximab Drugs 0.000 description 1
- 229950010626 pagibaximab Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229950003570 panobacumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- XLCISDOVNFLSGO-VONOSFMSSA-N phorbol-12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(O)C1(C)C XLCISDOVNFLSGO-VONOSFMSSA-N 0.000 description 1
- 229950003486 ponezumab Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229950011407 pritoxaximab Drugs 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229950002786 rafivirumab Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229950005854 regavirumab Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229950003850 setoxaximab Drugs 0.000 description 1
- 229950004951 sevirumab Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229950001915 suvizumab Drugs 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229950008836 tosatoxumab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 229950005082 tuvirumab Drugs 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- the present disclosure relates to the field of pharmaceuticals; more particularly, to multi-functional molecular constructs, e.g., those having targeting and effector elements for delivering the effector (e.g., therapeutic drug) to targeted sites.
- multi-functional molecular constructs e.g., those having targeting and effector elements for delivering the effector (e.g., therapeutic drug) to targeted sites.
- antibodies can neutralize or trap disease-causing mediators, which may be cytokines or immune components present in the blood circulation, interstitial space, or in the lymph nodes.
- the neutralizing activity inhibits the interaction of the disease-causing mediators with their receptors.
- fusion proteins of the soluble receptors or the extracellular portions of receptors of cytokines and the Fc portion of IgG which act by neutralizing the cytokines or immune factors in a similar fashion as neutralizing antibodies, have also been developed as therapeutic agents.
- Fc-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis (CMC), are not the intended mechanisms for the antibodies.
- Some therapeutic antibodies bind to certain surface antigens on target cells and render Fc-mediated functions and other mechanisms on the target cells.
- the most important Fc-mediated mechanisms are antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis (CMC), which both will cause the lysis of the antibody-bound target cells.
- ADCC antibody-dependent cellular cytotoxicity
- CMC complement-mediated cytolysis
- Some antibodies binding to certain cell surface antigens can induce apoptosis of the bound target cells.
- the bi-valent or multivalent antibodies may contain two or more antigen-binding sites.
- a number of methods have been reported for preparing multivalent antibodies by covalently linking three or four Fab fragments via a connecting structure.
- antibodies have been engineered to express tandem three or four Fab repeats.
- the present disclosure is directed to a fragment crystallizable (Fc)-based molecular construct that has at least one targeting element and at least one effector element linked, directly or indirectly, to a CH2-CH3 domain of an immunoglobulin.
- Targeting and effector elements of the present Fc-based molecular constructs are specifically selected such that these Fc-based molecular constructs are suitable for use in the treatment of central nervous system (CNS) diseases, or for use in the manufacture of a medicament for treating CNS diseases.
- CNS central nervous system
- methods for treating CNS diseases using such Fc-based molecular constructs also fall within the aspect of the present disclosure.
- the Fc-based molecular construct comprises a pair of CH2-CH3 segments of an IgG.Fc, a pair of effector elements, and a pair of targeting elements.
- the pair of effector element is interferon ⁇ 1a (INF- ⁇ 1a) or INF- ⁇ 1b, or an antibody fragment specific for integrin ⁇ 4 or ⁇ -amyloid, while the pair targeting elements is an antibody fragment specific for human transferrin receptor or human insulin receptor.
- the pair of targeting elements is linked to the C-termini of the pair of CH2-CH3 segments, and vice versa.
- the pair of effectors elements and the pair of targeting elements is both in the form of single-chain variable fragments (scFvs)
- the pair of targeting elements is linked to the N-termini of the pair of effector elements in a tandem or diabody configuration, thereby forming a pair of bispecific scFvs that are linked to the N-termini of the pair of CH2-CH3 segments.
- the pair of CH2-CH3 segments is derived from human IgG heavy chain ⁇ 4 or human IgG heavy chain ⁇ 1.
- the pair of effector elements or the pair of the targeting elements takes a Fab configuration (i.e., consisting of the V H -CH1 domain and the V L -C ⁇ domain); this Fab fragment is linked to the N-termini of the first and second heavy chains, so that the Fc-based molecular construct adopts an IgG configuration.
- the pair of elements that is not in the Fab configuration is linked to the C-termini of the pair of CH2-CH3 segments.
- the effector element is INF- ⁇ 1a, INF- ⁇ 1b, or an scFv specific for integrin ⁇ 4, while the targeting element is an scFv specific for human transferrin receptor.
- this molecular construct is suitable for treating multiple sclerosis.
- the effector element is an scFv specific for ⁇ -amyloid
- the targeting element is an scFv specific for human transferrin receptor.
- this molecular construct is suitable for treating Alzheimer's disease.
- Methods for treating CNS diseases in a subject in need thereof comprise the step of administering to the subject an effective amount of the molecular construct of this aspect.
- CNS diseases treatable by this method include multiple sclerosis and Alzheimer's disease.
- the present disclosure is directed to a fragment crystallizable (Fc)-based molecular construct that has at least one targeting element and at least one effector element linked, directly or indirectly, to a CH2-CH3 domain of an immunoglobulin.
- Targeting and effector elements of the present Fc-based molecular constructs are specifically selected such that these Fc-based molecular constructs are suitable for use in the treatment of diseases/conditions associated with viral or bacterial infection, or for use in the manufacture of a medicament for treating such diseases/conditions.
- methods for treating diseases/conditions associated with viral or bacterial infection using such Fc-based molecular constructs also fall within the aspect of the present disclosure.
- the Fc-based molecular construct comprises a pair of CH2-CH3 segments of an IgG.Fc, a pair of effector elements, and a pair of targeting elements.
- the pair of effector element is an antibody fragment specific for CD32 or CD16b
- the pair targeting elements is an antibody fragment specific for a viral protein or a bacterial protein.
- the pair of targeting elements is linked to the C-termini of the pair of CH2-CH3 segments, and vice versa.
- the pair of effectors elements and the pair of targeting elements is both in the form of single-chain variable fragments (scFvs)
- the pair of targeting elements is linked to the N-termini of the pair of effector elements in a tandem or diabody configuration, thereby forming a pair of bispecific scFvs that are linked to the N-termini of the pair of CH2-CH3 segments.
- the pair of CH2-CH3 segments is derived from human IgG heavy chain ⁇ 4 or human IgG heavy chain ⁇ 1.
- the pair of effector elements or the pair of the targeting elements takes a Fab configuration (i.e., consisting of the V H -CH1 domain and the V L -C ⁇ domain); this Fab fragment is linked to the N-termini of the first and second heavy chains, so that the Fc-based molecular construct adopts an IgG configuration.
- the pair of elements that is not in the Fab configuration is linked to the C-termini of the pair of CH2-CH3 segments.
- the effector element is an scFv specific for CD32 or CD16b
- the targeting element is an scFv specific for a viral protein.
- the viral protein can be F protein of respiratory syncytia virus (RSV), gp120 protein of human immunodeficiency virus type 1 (HIV-1), hemagglutinin A (HA) protein of influenza A virus, or glycoprotein of cytomegalovirus.
- RSV respiratory syncytia virus
- HAV-1 human immunodeficiency virus type 1
- HA hemagglutinin A
- this molecular construct is suitable for treating viral infections.
- the effector element is an scFv specific for Cd35 or C16b
- the targeting element is an scFv specific for a bacterial protein.
- the bacterial protein include, but are not limited to, the endotoxin of Gram( ⁇ ) bacteria, the surface antigen of Clostridium difficile , the lipoteichoic acid of Staphylococcus aureus , the anthrax toxin of Bacillus anthracis , or the Shiga-like toxin type I or II of Escherichia coli .
- such molecular construct is suitable for treating bacterial infections.
- Methods for treating diseases/conditions associated with infections comprise the step of administering to the subject an effective amount of the molecular construct of this aspect.
- FIGS. 1A to 1C are schematic diagrams illustrating Fc-based molecular constructs according to various embodiments of the present disclosure.
- FIG. 2 is a schematic diagram illustrating an Fc-based molecular construct according to various embodiments of the present disclosure.
- FIGS. 3A and 3B are schematic diagrams illustrating an Fc-based molecular constructs according to various embodiments of the present disclosure.
- FIG. 4A shows the SDS-PAGE analysis result of purified recombinant 2-chain (scFv ⁇ RSV)-hIgG1.Fc-(scFv ⁇ CD32) fusion protein
- FIG. 4B and FIG. 4C provide the results of ELISA analyses that respectively illustrate the binding activities of the purified recombinant fusion protein of FIG. 4A to Protein F of RSV ( FIG. 30B ) and to ectodomain of CD32a ( FIG. 30C ).
- FIG. 5A shows the SDS-PAGE analysis result of the purified recombinant 2-chain (scFv ⁇ endotoxin)-hIgG1.Fc-(scFv ⁇ CD32) fusion protein; and FIG. 5B and FIG. 31C provides the results of ELISA analyses that respectively illustrate the binding affinity of the purified recombinant fusion protein of FIG. 5A to endotoxin ( FIG. 5B ) and to ectodomain of CD32a ( FIG. 5C ).
- FIG. 6A and FIG. 6B respectively show the SDS-PAGE analysis result and the ELISA results of the purified recombinant 2-chain (Interferon- ⁇ -1a)-hIgG4.Fc-(scFv ⁇ TfR1) fusion protein.
- FIG. 7A and FIG. 7B respectively shows the SDS-PAGE analysis result and staining result of the purified recombinant 2-chain (scFv ⁇ integrin ⁇ 4)-hIgG4.Fc-(scFv ⁇ TfR1) fusion protein.
- FIG. 8 shows the ELISA analysis result of the effect of the purified recombinant 2-chain (scFv ⁇ endotoxin)-hIgG1.Fc-(scFv ⁇ CD32a) fusion protein on inhibiting TNF- ⁇ secretion.
- phrases “at least one of A, B, and C”, “at least one of A, B, or C” and “at least one of A, B and/or C,” as use throughout this specification and the appended claims, are intended to cover A alone, B alone, C alone, A and B together, B and C together, A and C together, as well as A, B, and C together.
- each molecular construct comprises a targeting element (T) and an effector element (E), and these molecular constructs are sometimes referred to as “T-E molecules”, “T-E pharmaceuticals” or “T-E drugs” in this document.
- the term “targeting element” refers to the portion of a molecular construct that directly or indirectly binds to a target of interest (e.g., a receptor on a cell surface or a protein in a tissue) thereby facilitates the transportation of the present molecular construct into the interested target.
- the targeting element may direct the molecular construct to the proximity of the target cell.
- the targeting element specifically binds to a molecule present on the target cell surface or to a second molecule that specifically binds a molecule present on the cell surface.
- the targeting element may be internalized along with the present molecular construct once it is bound to the interested target, hence is relocated into the cytosol of the target cell.
- a targeting element may be an antibody or a ligand for a cell surface receptor, or it may be a molecule that binds such antibody or ligand, thereby indirectly targeting the present molecular construct to the target site (e.g., the surface of the cell of choice).
- the localization of the effector (therapeutic agent) in the diseased site will be enhanced or favored with the present molecular constructs as compared to the therapeutic without a targeting function.
- the localization is a matter of degree or relative proportion; it is not meant for absolute or total localization of the effector to the diseased site.
- the term “effector element” refers to the portion of a molecular construct that elicits a biological activity (e.g., inducing immune responses, exerting cytotoxic effects and the like) or other functional activity (e.g., recruiting other hapten tagged therapeutic molecules), once the molecular construct is directed to its target site.
- the “effect” can be therapeutic or diagnostic.
- the effector elements encompass those that bind to cells and/or extracellular immunoregulatory factors.
- the effector element comprises agents such as proteins, nucleic acids, lipids, carbohydrates, glycopeptides, drug moieties (both small molecule drug and biologics), compounds, elements, and isotopes, and fragments thereof.
- first, second, third, etc. may be used herein to describe various elements, components, regions, and/or sections, these elements (as well as components, regions, and/or sections) are not to be limited by these terms. Also, the use of such ordinal numbers does not imply a sequence or order unless clearly indicated by the context. Rather, these terms are simply used to distinguish one element from another. Thus, a first element, discussed below, could be termed a second element without departing from the teachings of the exemplary embodiments.
- link refers to any means of connecting two components either via direct linkage or via indirect linkage between two components.
- polypeptide refers to a polymer having at least two amino acid residues. Typically, the polypeptide comprises amino acid residues ranging in length from 2 to about 200 residues; preferably, 2 to 50 residues. Where an amino acid sequence is provided herein, L-, D-, or beta amino acid versions of the sequence are also contemplated. Polypeptides also include amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
- the term applies to amino acids joined by a peptide linkage or by other, “modified linkages,” e.g., where the peptide bond is replaced by an ⁇ -ester, a ⁇ -ester, a thioamide, phosphoramide, carbomate, hydroxylate, and the like.
- conservative substitutions of the amino acids comprising any of the sequences described herein are contemplated.
- one, two, three, four, or five different residues are substituted.
- the term “conservative substitution” is used to reflect amino acid substitutions that do not substantially alter the activity (e.g., biological or functional activity and/or specificity) of the molecule.
- conservative amino acid substitutions involve substitution one amino acid for another amino acid with similar chemical properties (e.g., charge or hydrophobicity).
- Certain conservative substitutions include “analog substitutions” where a standard amino acid is replaced by a non-standard (e.g., rare, synthetic, etc.) amino acid differing minimally from the parental residue. Amino acid analogs are considered to be derived synthetically from the standard amino acids without sufficient change to the structure of the parent, are isomers, or are metabolite precursors.
- polypeptides comprising at least 80%, preferably at least 85% or 90%, and more preferably at least 95% or 98% sequence identity with any of the sequences described herein are also contemplated.
- Percentage (%) amino acid sequence identity with respect to the polypeptide sequences identified herein is defined as the percentage of polypeptide residues in a candidate sequence that are identical with the amino acid residues in the specific polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percentage sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
- sequence comparison between two polypeptide sequences was carried out by computer program Blastp (protein-protein BLAST) provided online by National Center for Biotechnology Information (NCBI).
- Blastp protein-protein BLAST
- NCBI National Center for Biotechnology Information
- X is the number of amino acid residues scored as identical matches by the sequence alignment program BLAST in that program's alignment of A and B, and where Y is the total number of amino acid residues in A or B, whichever is shorter.
- PEGylated amino acid refers to a polyethylene glycol (PEG) chain with one amino group and one carboxyl group.
- PEG polyethylene glycol
- the PEGylated amino acid has the formula of NH 2 —(CH 2 CH 2 O) n —COOH.
- n ranges from 1 to 20; preferably, ranging from 2 to 12.
- terminal refers to an amino acid residue at the N- or C-end of the polypeptide.
- terminal refers to a constitutional unit of the polymer (e.g., the polyethylene glycol of the present disclosure) that is positioned at the end of the polymeric backbone.
- free terminus is used to mean the terminal amino acid residue or constitutional unit is not chemically bound to any other molecular.
- antigen or “Ag” as used herein is defined as a molecule that elicits an immune response. This immune response may involve a secretory, humoral and/or cellular antigen-specific response.
- the term “antigen” can be any of a protein, a polypeptide (including mutants or biologically active fragments thereof), a polysaccharide, a glycoprotein, a glycolipid, a nucleic acid, or a combination thereof.
- antibody is used in the broadest sense and covers fully assembled antibodies, antibody fragments that bind with antigens, such as antigen-binding fragment (Fab/Fab′), F(ab′) 2 fragment (having two antigen-binding Fab portions linked together by disulfide bonds), variable fragment (Fv), single chain variable fragment (scFv), bi-specific single-chain variable fragment (bi-scFv), nanobodies, unibodies and diabodies.
- Fab/Fab′ antigen-binding fragment
- F(ab′) 2 fragment having two antigen-binding Fab portions linked together by disulfide bonds
- variable fragment Fv
- scFv single chain variable fragment
- bi-specific single-chain variable fragment bi-scFv
- nanobodies unibodies and diabodies.
- an “antibody” refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes.
- the well-known immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as myriad immunoglobulin variable region genes.
- Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively.
- a typical immunoglobulin (antibody) structural unit is known to comprise a tetramer.
- Each tetramer is composed of two identical pairs of polypeptide chains, with each pair having one “light” chain (about 25 kDa) and one “heavy” chain (about 50-70 kDa).
- the N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- the terms variable light chain (V L ) and variable heavy chain (V H ) refer to these light and heavy chains, respectively.
- the antibody fragment can be produced by modifying the nature antibody or by de novo synthesis using recombinant DNA methodologies.
- the antibody and/or antibody fragment can be bispecific, and can be in various configurations.
- bispecific antibodies may comprise two different antigen binding sites (variable regions).
- bispecific antibodies can be produced by hybridoma technique or recombinant DNA technique.
- bispecific antibodies have binding specificities for at least two different epitopes.
- the term “specifically binds” as used herein, refers to the ability of an antibody or an antigen-binding fragment thereof, to bind to an antigen with a dissociation constant (Kd) of no more than about 1 ⁇ 10 ⁇ 6 M, 1 ⁇ 10 ⁇ 7 M, 1 ⁇ 10 ⁇ 8 M, 1 ⁇ 10 ⁇ 9 M, 1 ⁇ 10 ⁇ 10 M, 1 ⁇ 10 ⁇ 11 M, 1 ⁇ 10 ⁇ 12 M, and/or to bind to an antigen with an affinity that is at least two-folds greater than its affinity to a nonspecific antigen.
- Kd dissociation constant
- treatment includes preventative (e.g., prophylactic), curative or palliative treatment; and “treating” as used herein also includes preventative (e.g., prophylactic), curative or palliative treatment.
- treating refers to the application or administration of the present molecular construct or a pharmaceutical composition comprising the same to a subject, who has a medical condition a symptom associated with the medical condition, a disease or disorder secondary to the medical condition, or a predisposition toward the medical condition, with the purpose to partially or completely alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of said particular disease, disorder, and/or condition.
- Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition, and/or to a subject who exhibits only early signs of a disease, disorder and/or condition, for the purpose of decreasing the risk of developing pathology associated with the disease, disorder and/or condition.
- an effective amount refers to the quantity of the present molecular construct that is sufficient to yield a desired therapeutic response.
- An effective amount of an agent is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered or prevented, or the disease or condition symptoms are ameliorated.
- the effective amount may be divided into one, two, or more doses in a suitable form to be administered at one, two or more times throughout a designated time period.
- Effective amount will vary with such factors as particular condition being treated, the physical condition of the patient (e.g., the patient's body mass, age, or gender), the type of subject being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives. Effective amount may be expressed, for example, as the total mass of active component (e.g., in grams, milligrams or micrograms) or a ratio of mass of active component to body mass, e.g., as milligrams per kilogram (mg/kg).
- application and “administration” are used interchangeably herein to mean the application of a molecular construct or a pharmaceutical composition of the present invention to a subject in need of a treatment thereof.
- subject and patient are used interchangeably herein and are intended to mean an animal including the human species that is treatable by the molecular construct, pharmaceutical composition, and/or method of the present invention.
- subject or patient intended to refer to both the male and female gender unless one gender is specifically indicated. Accordingly, the term “subject” or “patient” comprises any mammal, which may benefit from the treatment method of the present disclosure.
- Examples of a “subject” or “patient” include, but are not limited to, a human, rat; mouse; guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl.
- the patient is a human.
- mammal refers to all members of the class Mammalia, including humans, primates, domestic and farm animals, such as rabbit, pig, sheep, and cattle; as well as zoo, sports or pet animals; and rodents, such as mouse and rat.
- non-human mammal refers to all members of the class Mammalis except human.
- the present disclosure is based, at least on the construction of the T-E pharmaceuticals that can be delivered to target cells, target tissues or organs at increased proportions relative to the blood circulation, lymphoid system, and other cells, tissues or organs.
- the therapeutic effect of the pharmaceuticals is increased, while the scope and severity of the side effects and toxicity is decreased.
- a therapeutic effector is administered at a lower dosage in the form of a T-E molecule, than in a form without a targeting component. Therefore, the therapeutic effector can be administered at lower dosages without losing potency, while lowering side effects and toxicity.
- Drugs used for many diseases can be improved for better efficacy and safety, if they can be targeted to the disease sites, i.e., if they can be localized or partitioned to the disease sites more favorably than the normal tissues or organs.
- Certain antibody drugs which target infectious microorganisms or their toxic products, can be improved, if they are empowered with the ability to recruit immunocytes, which phagocytose and clear the antibody-bound particles.
- drugs can be improved if they can be preferentially distributed to the disease sites or cells or if they can recruit phagocytic immunocytes.
- the therapeutic agents are often required to pass through the blood-brain barrier (BBB) to get into the CNS.
- BBB blood-brain barrier
- Some therapeutic agents do not get into the CNS; they regulate certain activities, such as immune activities, in the peripheral, which then modulates the diseased conditions in the CNS.
- the BBB is formed by the endothelial cells lining the capillaries of blood vessels in the CNS. Unlike the capillaries in the peripheral tissues and organs, the capillary endothelial cells in the BBB are connected by tight junctions formed by occludin, claudins, and junctional adhesion molecules.
- At least six antibodies namely, aducanumab, bapinerumab, crenezumab, gantenerumab, ponezumab, and solanezumab, specific for ⁇ -amyloid, which is responsible for causing Alzheimer's disease, have been developed and placed in clinical development. These antibodies generally fall short of satisfactory therapeutic efficacy in improving Alzheimer's disease. A general belief is that if those antibodies are to achieve therapeutic efficacy, a significant portion must get across the BBB to enter the injured sites in the CNS. However, only very minute portions of those antibodies get across the BBB.
- Interferon- ⁇ -1a IFN- ⁇ -1a
- IFN- ⁇ -1b interferon- ⁇ -1b
- MS multiple sclerosis
- the pharmaceuticals, IFN- ⁇ -1a produced by mammalian cells and IFN- ⁇ -1b produced in E. coli are one-chain protein of 166 amino acid residues containing one disulfide bond. It has been claimed that those therapeutic agents reduce relapse of MS in 18-38% of treated patients.
- the mechanisms of action of IFN- ⁇ -1a and IFN- ⁇ -1b are very complex and not completely understood, involving the increased generation of anti-inflammatory immune cells and factors and the down-regulation of pro-inflammatory cells and factors.
- IFN- ⁇ treatment in MS patients also reduces the trafficking of pro-inflammatory T cells across the BBB. It is yet unanswered whether IFN- ⁇ -1a and IFN- ⁇ -1b mediate their pharmacologic effects in part by getting into the injured sites in the CNS.
- natalizumab specific for the cell adhesion molecule integrin ⁇ 4.
- the antibody functions by inhibiting inflammatory immune cells to attach to and pass through the epithelial layer lining the BBB. While natalizumab has been shown to be therapeutic efficacious, it has serious immunosuppressive side effect. In particular, it causes progressive multifocal leukoencephalopathy, an opportunistic infection caused by John Cunningham virus (JC virus).
- JC virus John Cunningham virus
- the endothelial cells in the capillaries forming the BBB express transferrin receptors and insulin receptors, which mediate the transcytosis of transferrin and insulin molecules, respectively, to the cerebral parenchyma.
- transferrin receptor As a ferry, only a small proportion gets through while the reaming bulk are trapped or degraded.
- the transferrin receptors on the endothelial cells in the BBB can serve as site-specific antigen for recruiting administered therapeutics. Once the therapeutic is concentrated in the BBB, an increased proportion of it will pass through the capillaries.
- anti-inflammatory drugs such as anti-TNF- ⁇ , anti-IL12/IL-23, anti-IL17, and anti-CD3, should be investigated for their therapeutic effects on many types of diseases of the CNS.
- the transferrin receptor is used as a target site recruiter.
- the effector moiety can be a few copies of scFv specific for ⁇ -amyloid; for treating multiple sclerosis, the effector moiety can be a few copies of IFN- ⁇ -1a or IFN- ⁇ -1b, or a few copies of scFv specific for integrin ⁇ 4.
- Embodiments of the present disclosure disclose several T-E molecules respectively exist in single multi-arm linker-units or joint-linker configurations, each contains scFv specific for transferrin receptor as the targeting element and IFN- ⁇ -1a or IFN- ⁇ -1b or scFv specific for integrin ⁇ -4 as the effector element.
- Alternative embodiments disclose T-E molecules respectively exist in single linker-units or joint-linker configurations, each contains scFv specific for transferrin receptor as the targeting element and scFv specific for ⁇ -amyloid as the effector element.
- Fingolimod is an immunosuppressive drug that is derived from a natural product myriocin originally isolated from certain fungi. Fingolimod has been approved for reducing the relapse of relapsing-remitting multiple sclerosis. Fingolimod is phosphorylated in vivo to form fingolimod-phosphate, which resembles naturally occurring sphingosine-1-phosphate (S1P), an extracellular lipid mediator, and can bind to 4 of the 5 S1P receptors. The S1P receptors are expressed on lymphocytes and involved in lymphocyte migration. A generally pharmacologic mechanism of fingolimod is that it inhibits lymphocytes egress from the lymphoid tissues to the circulation and hence to the CNS.
- S1P sphingosine-1-phosphate
- Fingolimod can cross BBB to enter CNS and many cell types in the CNS express S1P receptors, which play roles in cell proliferation, morphology, and migration. It is believed that fingolimod can have direct on the CNS.
- the administration of fingolimod causes common side effects of headache and fatigue, and severe side effects of skin cancer, macular edema, and fatal infections, such as hemorrhaging focal encephalitis.
- a fingolimod molecule has an NH2 group and thus provides a functional group to couple with a bi-functional linker with an NHS group.
- One preferred embodiment of the present invention is to prepare a T-E construct, which contains a targeting element for delivery to the BBB and a drug bundle of fingolimod as an effector element.
- a bundle of fingolimod 5-10 molecules are incorporated to a linker unit, using either a cleavable linker or non-cleavable linker to conjugate fingolimod molecules to the linking arms of a linker unit.
- fingolimod Since fingolimod, after uptake in a patient, is modified to fingolimod phosphate to resemble sphingosine1-phosphate and become active, the drug bundle is alternatively prepared with fingolimod phosphate.
- a linker unit with fingolimod or fingolimod phosphate bundle is conjugated with 1 or 2 scFv specific for a transferrin receptor I.
- Upon administration of the molecular construct a portion of it is carried to the BBB.
- the fingolimod molecules released from the cleavable linkers pass through the BBB and enter the CNS. Or, a portion of the entire construct enters the CNS.
- Cleavable linkers can be designed by employing a number of cleaving mechanisms.
- S—S bond An installment of S—S bond is often used, since S—S disulfide bond can be cleaved by a reduction reaction at the target tissue site.
- a peptide bond between amino acids which is sensitive to proteases, such as matrix metalloproteinases in many tissues and cathepsins in endosomes in target cells, is also commonly used as a cleavable bond in many linker designs.
- the T-E molecular design of the present invention can also be applied for the prevention and treatment of infectious diseases.
- the plurality of the linking arms can enhance the avidity and specificity of binding to target infectious microorganisms or their products and elicit immune functions to facilitate the clearance of the microorganisms and their products.
- Such improvements should increase the efficacy of the candidate antibodies for the prevention and therapy of infectious diseases.
- Many antibodies, which have failed to meet expectation in clinical trials, may be configured with the present invention and re-investigated.
- a preferred set of embodiment of the present invention is to employ joint-linkers configuration with one linker-unit for targeting and one linker-unit for recruiting effector function.
- An alternative set of preferred embodiment is to employ single linker-units with multiple linking arms for targeting elements and a coupling arm for an effector element.
- the targeting elements may be one of the two categories: (1) scFv or sdAb specific for a surface component of a microorganism or its product, e.g., envelope protein gp120 of human immunodeficiency virus type 1 (HIV-1), F protein of respiratory syncytia virus (RSV), a surface antigen of Clostridium difficile or Staphylococcus aureus , or endotoxin of Gram-negative bacteria or Shiga-like toxin of Escherichia coli , or (2) the extracellular portions of cell surface receptors of viruses, such as the HIV-1 gp120-binding CD4 domain.
- HIV-1 human immunodeficiency virus type 1
- RSV respiratory syncytia virus
- the effector elements are 1 or 2 scFv or sdAb specific for one Fc receptor of IgG, e.g. Fc ⁇ RIIA (CD32), Fc ⁇ RIIIB (CD16b), or Fc ⁇ RI (CD64).
- Fc ⁇ RIIA and Fc ⁇ RIIIB bind to IgG with low affinity (Kd in the range of 10 ⁇ 6 to 10 ⁇ 7 ), and Fc ⁇ RI binds to IgG1 and IgG3 with high affinity (Kd 10 ⁇ 9 ).
- scFv or sdAb specific for Fc ⁇ RIIA or Fc ⁇ RIIIB because they can compete favorably with IgG in binding to the receptors.
- the antibodies specific for carbohydrate antigens on bacterial surface are usually weak in binding affinity and are expressed in IgM rather than IgG.
- An IgM molecule has 10 Fv's (antigen-binding sites).
- an IgM molecule which has a molecular weight of about 1000 kd, cannot cross capillaries and reach to extravascular space.
- a molecular construct carrying 6 scFv or 10 sdAb will have a molecular weight of about 150 kd.
- the molecular construct contains 2 or more scFv specific for an Fc ⁇ receptor and can bind to multiple Fc ⁇ receptor molecules on phagocyte cell surface, so that the bound viral particles are destined to phagocytosis pathway.
- immunoglobulin antibody can serve as the base of a targeting or effector element, and its corresponding effector or targeting element can be incorporated at the C-terminal of its two heavy ⁇ chains in the form of scFv domains.
- two-chain IgG.Fc is used as the base of the molecular platform.
- Each of the polypeptide chain is fused with one or two targeting and one or two effector elements, for a total of two to three elements on each chain.
- the T-E molecule with an Fc-based configuration will have a total of four to six elements (e.g., scFv or any other antibody fragments).
- the Fc portion of the molecular constructs also carries Fc-mediated effector functions, ADCC, and/or complement-mediated activation. While in certain other applications, such Fc-mediated effector functions are avoided.
- targeting elements are positioned at the N- or C-terminus. If the effector elements function by binding to a cell surface component, they should also be positioned at the terminus. If the effector elements function by binding to and neutralizing soluble factors, they can be positioned between a terminal targeting or effector element and CH2-CH3.
- the molecular construct can be used to treat central nervous system (CNS) diseases or infectious diseases.
- CNS central nervous system
- the present disclosure is also advantageous in that, in some embodiments, it utilizes the linker unit according to the first aspect of the present disclosure, which provides a facile means for controlling the number of the targeting and effector elements of the present Fc-based molecular constructs.
- the present Fc-based molecular construct may take different configurations, which are discussed below, respectively.
- both the targeting element and effector element are antibodies or fragments thereof.
- FIG. 1A is a schematic diagram illustrating an Fc-based molecular construct 800A according to certain embodiments of the present disclosure.
- the Fc-based molecular construct 800A comprises two identical CH2-CH3 chains 810, a pair of effector elements E1 linked to the N-termini of the CH2-CH3 chains 810, and a pair of targeting elements T1 linked to the C-termini of the CH2-CH3 chains 810.
- both the targeting element T1 and effector element E1 are scFvs.
- the Fc-based molecular construct 800B illustrated in FIG. 1B is quite similar to the Fc-based molecular construct 800A of FIG. 1A in structure, except that the two effector elements E1 are respectively linked to the C-termini of the CH2-CH3 chains 810, while the two targeting effectors are respectively linked to the C-termini of the CH2-CH3 chains 810.
- both the effector elements and targeting elements are linked to the N-termini of the CH2-CH3 chains.
- the effector element and the targeting element are in the form of single-chain variable fragments (scFvs)
- the effector element and the targeting element may be linked in a tandem or diabody configuration, thereby forming a bispecific scFv that is linked to the N-terminus of the CH2-CH3 chain.
- the Fc-based molecular construct 800C ( FIG. 1C ) comprises an Fc portion, and accordingly, each CH2-CH3 chain 810 has a T1-E1 bispecific scFv linked to the N-terminus thereof.
- the pair of effector elements or the pair of the targeting elements takes a Fab configuration (i.e., consisting of the V H -CH1 domain and the V L -C ⁇ domain); this Fab fragment is linked to the N-termini of the CH2-CH3 chains, so that the Fc-based molecular construct adopts an IgG configuration.
- the pair of elements that is not in the Fab configuration may be linked to the C-termini of the pair of CH2-CH3 segments.
- each of the two targeting elements T1 comprises the V H -CH1 domain 820 and the V L -C ⁇ domain 825, thereby forming a Fab configuration 830 that is linked to the N-termini of the CH2-CH3 chains 810, so that the Fc-based molecular construct 900 adopts the IgG configuration.
- the pair of effector elements E1 is linked to the C-termini of the pair of CH2-CH3 chains 810.
- the present Fc-based molecular construct has an effector element which is a peptide.
- the effector element can be a peptide with certain therapeutic effect, while the targeting element is an antibody or a fragment thereof (see, FIGS. 3A and 3B ).
- the Fc-based molecular construct 1000A of FIG. 3A comprises a pair of targeting elements T1 (as scFvs) linked to the N-termini of the pair of CH2-CH3 segments 1210, and a pair of effector elements E1 (in the form of therapeutic peptides) linked to the C-termini of the pair of CH2-CH3 segments 1210.
- the pair of targeting elements T1 (as scFvs) is linked to the C-termini of the pair of CH2-CH3 segments 1210
- the pair of effector elements E1 (in the form of therapeutic peptides) is linked to the C-termini of the pair of CH2-CH3 segments 1210.
- the targeting element can be constructed into a Fab fragment, so that the molecular constructs take the IgG configuration.
- the CH2-CH3 chains are adopted from human immunoglobulins ⁇ 1 or ⁇ 4.
- ⁇ 1 is chosen, when Fc-mediated functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated activity (inflammatory activation or target cell lysis), are desired.
- ADCC antibody-dependent cellular cytotoxicity
- complement-mediated activity inflammatory activation or target cell lysis
- an antibody (or a fragment thereof) specific for transferrin receptor can be used as the targeting element, in connection with effector elements suitable for the particular CNS disease.
- Fc-based molecular constructs for the treatment of multiple sclerosis may use an scFv specific for integrin- ⁇ 4 as the effector element.
- illustrative Fc-based molecular constructs can use an scFv specific for ⁇ -amyloid as the effector element.
- the above-mentioned Fc-based molecular constructs for treating CNS diseases may take the configuration described in connection with any of FIGS. 1A to 1C , and FIG. 2 .
- Fc-based molecular constructs for treating multiple sclerosis may also use INF- ⁇ 1a or INF- ⁇ 1b as the effector elements.
- the Fc-based molecular constructs may take the configuration described in connection with FIG. 3A or 3B .
- Fc-based molecular constructs for treating diseases/conditions associated with infection such as viral infections or bacterial infections
- an antibody (or a fragment thereof) specific for a viral protein or bacterial protein as the targeting element.
- an antibody (or a fragment thereof) specific for CD32 or CD16b can be used.
- the essence of this invention is the rationalization and conception of the specific combination or pairing of the targeting and effector elements.
- the adoption of Fc-fusion configuration in the molecular constructs is a preferred embodiment. It is conceivable for those skilled in the arts to link the pairs of targeting and effector elements of this invention employing other molecular platforms, such as peptides, proteins (e.g., albumin), polysaccharides, polyethylene glycol, and other types of polymers, which serve as a structural base for attaching multiple molecular elements.
- the present disclosure also pertains to method for treating CNS diseases using the suitable Fc-based molecular construct.
- the method comprises the step of administering to a subject in need of such treatment an effective amount of the Fc-based molecular construct according to embodiments of the present disclosure.
- the present disclosure further pertains to method for treating infections using the suitable Fc-based molecular construct.
- the method comprises the step of administering to a subject in need of such treatment an effective amount of the Fc-based molecular construct according to embodiments of the present disclosure.
- the scFv1-CH2-CH3-scFv2 (human ⁇ 1) recombinant chain was configured by fusing two scFvs, in which the first one specific for Protein F of RSV fused to the N-terminal of CH2 domain of IgG1.Fc through a flexible hinge region, while the second one specific for ectodomain of CD32a was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS) 3 .
- Both of the scFvs had an orientation of V L -linker-V H .
- the V L and V H in each of the two scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG.
- the sequence of the recombinant chain in the IgG1.Fc fusion protein molecular construct is shown as SEQ ID NO: 1.
- the gene-encoding sequence was placed in pcDNA3 expression cassette.
- Expi293F cells were seeded at a density of 2.0 ⁇ 10 6 viable cells/ml in Expi293F expression medium and maintained for 18 to 24 hours prior to transfection to ensure that the cells were actively dividing at the time of transfection.
- 7.5 ⁇ 10 8 cells in 255-ml medium in a 2-liter Erlenmeyer shaker flask were transfected by ExpiFectamineTM 293 transfection reagent. The transfected cells were incubated at 37° C.
- FIG. 4C shows binding activity of the recombinant Fc-fusion protein to ectodomain of CD32a.
- ELISA plates were coated with 5 ⁇ g/mL of recombinant ectodomain of CD32a.
- Recombinant 2-chain (scFv ⁇ RSV)-hIgG1.Fc-(scFv ⁇ CD32a) fusion protein was detected by HRP-conjugated goat anti-human IgG1.Fc.
- FIG. 4C shows that the recombinant 2-chain (scFv ⁇ RSV)-hIgG1.Fc-(scFv ⁇ CD32a) Fc-fusion protein has binding activity to recombinant ectodomain of CD32a.
- Recombinant 2-chain (scFv ⁇ endotoxin)-IgG1.Fc protein was used as a control antibody.
- the scFv1-CH2-CH3-scFv2 (human ⁇ 1) recombinant chain was configured by fusing two scFvs, in which the first one specific for endotoxin was fused to the N-terminal of CH2 domain of IgG1.Fc through a flexible hinge region, and the second one specific for ectodomain was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS) 3 .
- Both of the scFvs had an orientation of V L -linker-V H .
- the V L and V H in each of the two scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG.
- the sequence of the recombinant chain in the IgG1.Fc fusion protein molecular construct is shown as SEQ ID NO: 2.
- the expression of the constructed gene in Expi293F cells and the purification of the expressed fusion protein were performed as in preceding Examples. Characterization of the new construct was performed with SDS-PAGE and ELISA. The SDA-PAGE results in FIG. 5A shows that the recombinant chain of the new construct has a size of about 85 kDa, consistent with the expected size.
- FIG. 5B shows ELISA results of the recombinant 2-chain (scFv ⁇ endotoxin)-(scFv ⁇ CD32a)-hIgG1.Fc binding to E. coli LPS 0111:B4 (Sigma Aldrich).
- ELISA plates were coated with 50 ⁇ g/ml poly-L-lysine. Subsequently, the poly-L-lysine-coated plates were further coated with 10 ⁇ g/ml E. coli LPS 0111:B4.
- the recombinant fusion protein was detected by HRP-conjugated goat anti-human IgG.Fc.
- the ELISA results show that the present recombinant Fc-fusion protein has binding activity to E. coli LPS 0111:B4 (Sigma Aldrich);
- FIG. 5C shows that the recombinant Fc-fusion protein has binding activity to ectodomain of CD32a.
- the 2-chain IgG.Fc fusion protein was prepared by configuring (interferon- ⁇ -1a)-CH2-CH3-(scFv ⁇ TfR1) (human ⁇ 4) in a recombinant chain.
- the C-terminal of the interferon- ⁇ -1a was fused to the N-terminal of CH2 via a linker, GGGGSGGGASGGS.
- the scFv specific for ectodomain of TfR1 was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS) 3 .
- the scFv (specific for ectodomain of TfR1) had an orientation of V L -linker-V H .
- the V L and V H in the scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG.
- the sequence of the recombinant chain in the IgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 3.
- the gene-encoding sequence was placed in pcDNA3 expression cassette.
- Expi293F cells were seeded at a density of 2.0 ⁇ 10 6 viable cells/ml in Expi293F expression medium and maintained for 18 to 24 hours prior to transfection to ensure that the cells were actively dividing at the time of transfection.
- 7.5 ⁇ 10 8 cells in 255-ml medium in a 2-liter Erlenmeyer shaker flask were transfected by ExpiFectamineTM 293 transfection reagent. The transfected cells were incubated at 37° C.
- Binding activity of recombinant (Interferon- ⁇ -1a)-hIgG1.Fc-(scFv ⁇ TfR1) was assayed by ELISA using a 96-well plate coated with recombinant (Interferon- ⁇ -1a)-hIgG1.Fc-(scFv ⁇ TfR1) protein in 5 ⁇ g/ml concentration, 100 ⁇ l per well.
- the scFv specific for ectodomain of TfR1 is as a negative control.
- Recombinant 2-chain (Interferon- ⁇ -1a)-hIgG1.Fc-(scFv ⁇ TfR1) was detected by HRP-conjugated rabbit anti-human interferon- ⁇ polyclonal antibody (Santa Cruz Biotechnology, Dallas, USA).
- HRP-conjugated rabbit anti-human interferon- ⁇ polyclonal antibody Santa Cruz Biotechnology, Dallas, USA.
- 50 ⁇ l of TMB substrate was added for color development.
- the reaction was stopped by 50 ⁇ l of 1M HCl. Absorbance at 450 nm was measured with a plate reader, Each bar represents the mean OD450 value of duplicate samples.
- FIG. 6B shows ELISA analysis of the present the molecular construct.
- the ELISA results show that (Interferon- ⁇ -1a)-hIgG1.Fc-(scFv ⁇ TfR1) fusion protein bound specifically to recombinant ectodomain of TfR1 protein.
- the V L and V H of the scFv specific for integrin ⁇ 4 were from monoclonal antibody natalizumab.
- the 2-chain IgG.Fc fusion protein was prepared by configuring (scFv ⁇ integrin ⁇ 4)-CH2-CH3-(scFv ⁇ TfR1) (human ⁇ 4) in a recombinant chain.
- the C-terminal of the scFv specific for integrin ⁇ 4 was fused to the N-terminal of CH2 via a linker, GGGGSGGGASGGS.
- the scFv specific for ectodomain of TfR1 was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS) 3 .
- the result of 8% SDA-PAGE in FIG. 7A shows that the recombinant chain of the new construct has a size of about 85 kDa (indicated by arrow), consistent with the expected size.
- the two scFv had the orientation of V L -linker-V H .
- the V L and V H in each of the two scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG.
- the sequence of the recombinant chain in the IgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 4.
- Illustrated herein is the configuration of the prepared 2-chain (scFv ⁇ integrin ⁇ 4)-IgG4.Fc-(scFv ⁇ TfR1) molecular construct.
- Jurkat T cells 1 ⁇ 10 6 Jurkat T cells was maintained in the RPMI1640 medium supplemented with 10% FBS at a density of 1 ⁇ 10 5 . The cells were kept in 37° C. with 5% CO 2 in a humidified chamber. 1 ⁇ 10 6 Jurkat T cells were washed with the binding buffer (phosphate-buffered saline with 0.1% FBS, 2 mM EDTA and 20 ng/ml NaN 3 ) twice. 10 ⁇ g/ml of Human BD Fc BlockTM (BD Biosciences, San Jose, US) was added to the washed Jurkat T cells to block Fc receptor mediated.
- the binding buffer phosphate-buffered saline with 0.1% FBS, 2 mM EDTA and 20 ng/ml NaN 3
- FIG. 7B shows results of the cell staining analysis of recombinant 2-chain (scFv ⁇ integrin ⁇ 4)-IgG4.Fc-(scFv ⁇ TfR1) protein on integrin ⁇ 4-expressing Jurkat T cells.
- ELISA was to determine the amount of secreted TNF- ⁇ in the supernatant by macrophage-like U937 cells.
- U937 cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum (Gibco) and 100 U/ml penicillin-streptomycin (Gibco), at the density between 3 ⁇ 10 5 and 2 ⁇ 10 6 cells/ml. The cells were kept in 37° C. with 5% CO 2 in a humidified chamber. To differentiate U937 into macrophage-like cells, 1 ⁇ 10 6 cells/ml of U937 were incubated with 10 ng/ml of phorbol 12-myristate ⁇ -acetate (PMA, Sigma Aldrich). After 48 hours, non-adherent cells were removed, and adherent cells were washed and seeded into 96-well plates.
- PMA phorbol 12-myristate ⁇ -acetate
- TNF- ⁇ levels in U937 supernatant were measured using an ELISA kit from R&D Systems.
- the wells of ELISA plates (Greiner Bio-One) were coated with 4 ⁇ g/mL of capture antibody in PBS at 4° C. overnight. Wells were subsequently blocked by 0.5% in PBS for 1 hour and incubated with diluted culture supernatant for 2 hours. 400 ng/mL of biotin-labeled detection antibody was used followed by Streptavidin-HRP to detect bound TNF- ⁇ . Chromogenic reaction was carried out using TMB substrate (Clinical Science Products), and stopped by adding 1N HCl. Plates were read at 450 nm absorbance. Concentrations of TNF- ⁇ were determined by extrapolation from four-parameter logistic fit standard curves generated from dilutions of standard protein supplied by the manufacturer.
- FIG. 8 shows that recombinant 2-chain (scFv ⁇ endotoxin)-hIgG1 Fc-(scFv ⁇ CD32a) significantly reduced TNF- ⁇ secretion stimulated by E. coli LPS 0111:B4, compared to control antibodies 2-chain (scFv ⁇ endotoxin)-hIgG1 Fc protein and anti-CD32a scFv or medium alone.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
Description
- 1. Field of the Invention
- The present disclosure relates to the field of pharmaceuticals; more particularly, to multi-functional molecular constructs, e.g., those having targeting and effector elements for delivering the effector (e.g., therapeutic drug) to targeted sites.
- 2. Description of the Related Art
- The continual advancement of a broad array of methodologies for screening and selecting monoclonal antibodies (mAbs) for targeted antigens has helped the development of a good number of therapeutic antibodies for many diseases that were regarded as untreatable just a few years ago. According to Therapeutic Antibody Database, approximately 2,800 antibodies have been studied or are being planned for studies in human clinical trials, and approximately 80 antibodies have been approved by governmental drug regulatory agencies for clinical uses. The large amount of data on the therapeutic effects of antibodies has provided information concerning the pharmacological mechanisms how antibodies act as therapeutics.
- One major pharmacologic mechanism for antibodies acting as therapeutics is that, antibodies can neutralize or trap disease-causing mediators, which may be cytokines or immune components present in the blood circulation, interstitial space, or in the lymph nodes. The neutralizing activity inhibits the interaction of the disease-causing mediators with their receptors. It should be noted that fusion proteins of the soluble receptors or the extracellular portions of receptors of cytokines and the Fc portion of IgG, which act by neutralizing the cytokines or immune factors in a similar fashion as neutralizing antibodies, have also been developed as therapeutic agents.
- Several therapeutic antibodies that have been approved for clinical applications or subjected to clinical developments mediate their pharmacologic effects by binding to receptors, thereby blocking the interaction of the receptors with their ligands. For those antibody drugs, Fc-mediated mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis (CMC), are not the intended mechanisms for the antibodies.
- Some therapeutic antibodies bind to certain surface antigens on target cells and render Fc-mediated functions and other mechanisms on the target cells. The most important Fc-mediated mechanisms are antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytolysis (CMC), which both will cause the lysis of the antibody-bound target cells. Some antibodies binding to certain cell surface antigens can induce apoptosis of the bound target cells.
- The concept and methodology for preparing antibodies with dual specificities germinated more than three decades ago. In recent year, the advancement in recombinant antibody engineering methodologies and the drive to develop improved medicine has stimulated the development bi-specific antibodies adopting a large variety of structural configurations.
- For example, the bi-valent or multivalent antibodies may contain two or more antigen-binding sites. A number of methods have been reported for preparing multivalent antibodies by covalently linking three or four Fab fragments via a connecting structure. For example, antibodies have been engineered to express tandem three or four Fab repeats.
- Several methods for producing multivalent antibodies by employing synthetic crosslinkers to associate, chemically, different antibodies or binding fragments have been disclosed. One approach involves chemically cross-linking three, four, and more separately Fab fragments using different linkers. Another method to produce a construct with multiple Fabs that are assembled to one-dimensional DNA scaffold was provided. Those various multivalent Ab constructs designed for binding to target molecules differ among one another in size, half-lives, flexibility in conformation, and ability to modulate the immune system. In view of the foregoing, several reports have been made for preparing molecular constructs with a fixed number of effector elements or with two or more different kinds of functional elements (e.g., at least one targeting element and at least one effector element). However, it is often difficult to build a molecular construct with a particular combination of the targeting and effector elements either using chemical synthesis or recombinant technology. Accordingly, there exists a need in the related art to provide novel molecular platforms to build a more versatile molecule suitable for covering applications in a wide range of diseases.
- The following presents a simplified summary of the disclosure in order to provide a basic understanding to the reader. This summary is not an extensive overview of the disclosure and it does not identify key/critical elements of the present invention or delineate the scope of the present invention. Its sole purpose is to present some concepts disclosed herein in a simplified form as a prelude to the more detailed description that is presented later.
- <I> Molecular Construct for Treating Central Nervous System Diseases and Uses Thereof
- In this aspect, the present disclosure is directed to a fragment crystallizable (Fc)-based molecular construct that has at least one targeting element and at least one effector element linked, directly or indirectly, to a CH2-CH3 domain of an immunoglobulin. Targeting and effector elements of the present Fc-based molecular constructs are specifically selected such that these Fc-based molecular constructs are suitable for use in the treatment of central nervous system (CNS) diseases, or for use in the manufacture of a medicament for treating CNS diseases. As could be appreciated, methods for treating CNS diseases using such Fc-based molecular constructs also fall within the aspect of the present disclosure.
- According to certain embodiments of the present disclosure, the Fc-based molecular construct comprises a pair of CH2-CH3 segments of an IgG.Fc, a pair of effector elements, and a pair of targeting elements. The pair of effector element is interferon β1a (INF-β1a) or INF-β1b, or an antibody fragment specific for integrin α4 or β-amyloid, while the pair targeting elements is an antibody fragment specific for human transferrin receptor or human insulin receptor.
- In the case where the pair of effector elements is linked to the N-termini of the pair of CH2-CH3 segments, the pair of targeting elements is linked to the C-termini of the pair of CH2-CH3 segments, and vice versa. Alternatively, when the pair of effectors elements and the pair of targeting elements is both in the form of single-chain variable fragments (scFvs), then the pair of targeting elements is linked to the N-termini of the pair of effector elements in a tandem or diabody configuration, thereby forming a pair of bispecific scFvs that are linked to the N-termini of the pair of CH2-CH3 segments.
- In certain embodiments, the pair of CH2-CH3 segments is derived from human IgG heavy chain γ4 or human IgG heavy chain γ1.
- In some examples, the pair of effector elements or the pair of the targeting elements takes a Fab configuration (i.e., consisting of the VH-CH1 domain and the VL-Cκ domain); this Fab fragment is linked to the N-termini of the first and second heavy chains, so that the Fc-based molecular construct adopts an IgG configuration. In these cases, the pair of elements that is not in the Fab configuration is linked to the C-termini of the pair of CH2-CH3 segments.
- According to certain optional embodiments, the effector element is INF-β1a, INF-β1b, or an scFv specific for integrin α4, while the targeting element is an scFv specific for human transferrin receptor. In particular, this molecular construct is suitable for treating multiple sclerosis.
- According to other optional embodiments, the effector element is an scFv specific for β-amyloid, while the targeting element is an scFv specific for human transferrin receptor. In particular, this molecular construct is suitable for treating Alzheimer's disease.
- Methods for treating CNS diseases in a subject in need thereof comprise the step of administering to the subject an effective amount of the molecular construct of this aspect. CNS diseases treatable by this method include multiple sclerosis and Alzheimer's disease.
- <II> Molecular Construct for Treating Infectious Diseases
- In this aspect, the present disclosure is directed to a fragment crystallizable (Fc)-based molecular construct that has at least one targeting element and at least one effector element linked, directly or indirectly, to a CH2-CH3 domain of an immunoglobulin. Targeting and effector elements of the present Fc-based molecular constructs are specifically selected such that these Fc-based molecular constructs are suitable for use in the treatment of diseases/conditions associated with viral or bacterial infection, or for use in the manufacture of a medicament for treating such diseases/conditions. As could be appreciated, methods for treating diseases/conditions associated with viral or bacterial infection using such Fc-based molecular constructs also fall within the aspect of the present disclosure.
- According to certain embodiments of the present disclosure, the Fc-based molecular construct comprises a pair of CH2-CH3 segments of an IgG.Fc, a pair of effector elements, and a pair of targeting elements. The pair of effector element is an antibody fragment specific for CD32 or CD16b, while the pair targeting elements is an antibody fragment specific for a viral protein or a bacterial protein.
- In the case where the pair of effector elements is linked to the N-termini of the pair of CH2-CH3 segments, the pair of targeting elements is linked to the C-termini of the pair of CH2-CH3 segments, and vice versa. Alternatively, when the pair of effectors elements and the pair of targeting elements is both in the form of single-chain variable fragments (scFvs), then the pair of targeting elements is linked to the N-termini of the pair of effector elements in a tandem or diabody configuration, thereby forming a pair of bispecific scFvs that are linked to the N-termini of the pair of CH2-CH3 segments.
- In certain embodiments, the pair of CH2-CH3 segments is derived from human IgG heavy chain γ4 or human IgG heavy chain γ1.
- In some examples, the pair of effector elements or the pair of the targeting elements takes a Fab configuration (i.e., consisting of the VH-CH1 domain and the VL-Cκ domain); this Fab fragment is linked to the N-termini of the first and second heavy chains, so that the Fc-based molecular construct adopts an IgG configuration. In these cases, the pair of elements that is not in the Fab configuration is linked to the C-termini of the pair of CH2-CH3 segments.
- According to certain optional embodiments, the effector element is an scFv specific for CD32 or CD16b, while the targeting element is an scFv specific for a viral protein. For example, the viral protein can be F protein of respiratory syncytia virus (RSV), gp120 protein of human immunodeficiency virus type 1 (HIV-1), hemagglutinin A (HA) protein of influenza A virus, or glycoprotein of cytomegalovirus. In particular, this molecular construct is suitable for treating viral infections.
- According to other optional embodiments, the effector element is an scFv specific for Cd35 or C16b, while the targeting element is an scFv specific for a bacterial protein. Examples of the bacterial protein include, but are not limited to, the endotoxin of Gram(−) bacteria, the surface antigen of Clostridium difficile, the lipoteichoic acid of Staphylococcus aureus, the anthrax toxin of Bacillus anthracis, or the Shiga-like toxin type I or II of Escherichia coli. In particular, such molecular construct is suitable for treating bacterial infections.
- Methods for treating diseases/conditions associated with infections (e.g., viral or bacterial infections) in a subject in need thereof comprise the step of administering to the subject an effective amount of the molecular construct of this aspect.
- The present description will be better understood from the following detailed description read in light of the accompanying drawings briefly discussed below.
-
FIGS. 1A to 1C are schematic diagrams illustrating Fc-based molecular constructs according to various embodiments of the present disclosure. -
FIG. 2 is a schematic diagram illustrating an Fc-based molecular construct according to various embodiments of the present disclosure. -
FIGS. 3A and 3B are schematic diagrams illustrating an Fc-based molecular constructs according to various embodiments of the present disclosure. -
FIG. 4A shows the SDS-PAGE analysis result of purified recombinant 2-chain (scFv α RSV)-hIgG1.Fc-(scFv α CD32) fusion protein;FIG. 4B andFIG. 4C provide the results of ELISA analyses that respectively illustrate the binding activities of the purified recombinant fusion protein ofFIG. 4A to Protein F of RSV (FIG. 30B ) and to ectodomain of CD32a (FIG. 30C ). -
FIG. 5A shows the SDS-PAGE analysis result of the purified recombinant 2-chain (scFv α endotoxin)-hIgG1.Fc-(scFv α CD32) fusion protein; andFIG. 5B andFIG. 31C provides the results of ELISA analyses that respectively illustrate the binding affinity of the purified recombinant fusion protein ofFIG. 5A to endotoxin (FIG. 5B ) and to ectodomain of CD32a (FIG. 5C ). -
FIG. 6A andFIG. 6B respectively show the SDS-PAGE analysis result and the ELISA results of the purified recombinant 2-chain (Interferon-δ-1a)-hIgG4.Fc-(scFv α TfR1) fusion protein. -
FIG. 7A andFIG. 7B respectively shows the SDS-PAGE analysis result and staining result of the purified recombinant 2-chain (scFv α integrin α4)-hIgG4.Fc-(scFv α TfR1) fusion protein. -
FIG. 8 shows the ELISA analysis result of the effect of the purified recombinant 2-chain (scFv α endotoxin)-hIgG1.Fc-(scFv α CD32a) fusion protein on inhibiting TNF-α secretion. - In accordance with common practice, the various described features/elements are not drawn to scale but instead are drawn to best illustrate specific features/elements relevant to the present invention. Also, like reference numerals and designations in the various drawings are used to indicate like elements/parts, where possible.
- The detailed description provided below in connection with the appended drawings is intended as a description of the present examples and is not intended to represent the only forms in which the present example may be constructed or utilized. The description sets forth the functions of the example and the sequence of steps for constructing and operating the example. However, the same or equivalent functions and sequences may be accomplished by different examples.
- For convenience, certain terms employed in the specification, examples and appended claims are collected here. Unless otherwise defined herein, scientific and technical terminologies employed in the present disclosure shall have the meanings that are commonly understood and used by one of ordinary skill in the art.
- Unless otherwise required by context, it will be understood that singular terms shall include plural forms of the same and plural terms shall include the singular. Specifically, as used herein and in the claims, the singular forms “a” and “an” include the plural reference unless the context clearly indicated otherwise. Also, as used herein and in the claims, the terms “at least one” and “one or more” have the same meaning and include one, two, three, or more. Furthermore, the phrases “at least one of A, B, and C”, “at least one of A, B, or C” and “at least one of A, B and/or C,” as use throughout this specification and the appended claims, are intended to cover A alone, B alone, C alone, A and B together, B and C together, A and C together, as well as A, B, and C together.
- Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in the respective testing measurements. Also, as used herein, the term “about” generally means within 10%, 5%, 1% or 0.5% of a given value or range. Alternatively, the term “about” means within an acceptable standard error of the mean when considered by one of ordinary skill in the art. Other than in the operating/working examples, or unless otherwise expressly specified, all of the numerical ranges, amounts, values and percentages such as those for quantities of materials, durations of times, temperatures, operating conditions, ratios of amounts, and the likes thereof disclosed herein should be understood as modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present disclosure and attached claims are approximations that can vary as desired. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Ranges can be expressed herein as from one endpoint to another endpoint or between two endpoints. All ranges disclosed herein are inclusive of the endpoints, unless specified otherwise.
- This present disclosure pertains generally to molecular constructs, in which each molecular construct comprises a targeting element (T) and an effector element (E), and these molecular constructs are sometimes referred to as “T-E molecules”, “T-E pharmaceuticals” or “T-E drugs” in this document.
- As used herein, the term “targeting element” refers to the portion of a molecular construct that directly or indirectly binds to a target of interest (e.g., a receptor on a cell surface or a protein in a tissue) thereby facilitates the transportation of the present molecular construct into the interested target. In some example, the targeting element may direct the molecular construct to the proximity of the target cell. In other cases, the targeting element specifically binds to a molecule present on the target cell surface or to a second molecule that specifically binds a molecule present on the cell surface. In some cases, the targeting element may be internalized along with the present molecular construct once it is bound to the interested target, hence is relocated into the cytosol of the target cell. A targeting element may be an antibody or a ligand for a cell surface receptor, or it may be a molecule that binds such antibody or ligand, thereby indirectly targeting the present molecular construct to the target site (e.g., the surface of the cell of choice). The localization of the effector (therapeutic agent) in the diseased site will be enhanced or favored with the present molecular constructs as compared to the therapeutic without a targeting function. The localization is a matter of degree or relative proportion; it is not meant for absolute or total localization of the effector to the diseased site.
- According to the present invention, the term “effector element” refers to the portion of a molecular construct that elicits a biological activity (e.g., inducing immune responses, exerting cytotoxic effects and the like) or other functional activity (e.g., recruiting other hapten tagged therapeutic molecules), once the molecular construct is directed to its target site. The “effect” can be therapeutic or diagnostic. The effector elements encompass those that bind to cells and/or extracellular immunoregulatory factors. The effector element comprises agents such as proteins, nucleic acids, lipids, carbohydrates, glycopeptides, drug moieties (both small molecule drug and biologics), compounds, elements, and isotopes, and fragments thereof.
- Although the terms, first, second, third, etc., may be used herein to describe various elements, components, regions, and/or sections, these elements (as well as components, regions, and/or sections) are not to be limited by these terms. Also, the use of such ordinal numbers does not imply a sequence or order unless clearly indicated by the context. Rather, these terms are simply used to distinguish one element from another. Thus, a first element, discussed below, could be termed a second element without departing from the teachings of the exemplary embodiments.
- Here, the terms “link,” “couple,” and “conjugates” are used interchangeably to refer to any means of connecting two components either via direct linkage or via indirect linkage between two components.
- The term “polypeptide” as used herein refers to a polymer having at least two amino acid residues. Typically, the polypeptide comprises amino acid residues ranging in length from 2 to about 200 residues; preferably, 2 to 50 residues. Where an amino acid sequence is provided herein, L-, D-, or beta amino acid versions of the sequence are also contemplated. Polypeptides also include amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. In addition, the term applies to amino acids joined by a peptide linkage or by other, “modified linkages,” e.g., where the peptide bond is replaced by an α-ester, a β-ester, a thioamide, phosphoramide, carbomate, hydroxylate, and the like.
- In certain embodiments, conservative substitutions of the amino acids comprising any of the sequences described herein are contemplated. In various embodiments, one, two, three, four, or five different residues are substituted. The term “conservative substitution” is used to reflect amino acid substitutions that do not substantially alter the activity (e.g., biological or functional activity and/or specificity) of the molecule. Typically, conservative amino acid substitutions involve substitution one amino acid for another amino acid with similar chemical properties (e.g., charge or hydrophobicity). Certain conservative substitutions include “analog substitutions” where a standard amino acid is replaced by a non-standard (e.g., rare, synthetic, etc.) amino acid differing minimally from the parental residue. Amino acid analogs are considered to be derived synthetically from the standard amino acids without sufficient change to the structure of the parent, are isomers, or are metabolite precursors.
- In certain embodiments, polypeptides comprising at least 80%, preferably at least 85% or 90%, and more preferably at least 95% or 98% sequence identity with any of the sequences described herein are also contemplated.
- “Percentage (%) amino acid sequence identity” with respect to the polypeptide sequences identified herein is defined as the percentage of polypeptide residues in a candidate sequence that are identical with the amino acid residues in the specific polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percentage sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, sequence comparison between two polypeptide sequences was carried out by computer program Blastp (protein-protein BLAST) provided online by Nation Center for Biotechnology Information (NCBI). The percentage amino acid sequence identity of a given polypeptide sequence A to a given polypeptide sequence B (which can alternatively be phrased as a given polypeptide sequence A that has a certain % amino acid sequence identity to a given polypeptide sequence B) is calculated by the formula as follows:
-
- where X is the number of amino acid residues scored as identical matches by the sequence alignment program BLAST in that program's alignment of A and B, and where Y is the total number of amino acid residues in A or B, whichever is shorter.
- The term “PEGylated amino acid” as used herein refers to a polyethylene glycol (PEG) chain with one amino group and one carboxyl group. Generally, the PEGylated amino acid has the formula of NH2—(CH2CH2O)n—COOH. In the present disclosure, the value of n ranges from 1 to 20; preferably, ranging from 2 to 12.
- As used herein, the term “terminus” with respect to a polypeptide refers to an amino acid residue at the N- or C-end of the polypeptide. With regard to a polymer, the term “terminus” refers to a constitutional unit of the polymer (e.g., the polyethylene glycol of the present disclosure) that is positioned at the end of the polymeric backbone. In the present specification and claims, the term “free terminus” is used to mean the terminal amino acid residue or constitutional unit is not chemically bound to any other molecular.
- The term “antigen” or “Ag” as used herein is defined as a molecule that elicits an immune response. This immune response may involve a secretory, humoral and/or cellular antigen-specific response. In the present disclosure, the term “antigen” can be any of a protein, a polypeptide (including mutants or biologically active fragments thereof), a polysaccharide, a glycoprotein, a glycolipid, a nucleic acid, or a combination thereof.
- In the present specification and claims, the term “antibody” is used in the broadest sense and covers fully assembled antibodies, antibody fragments that bind with antigens, such as antigen-binding fragment (Fab/Fab′), F(ab′)2 fragment (having two antigen-binding Fab portions linked together by disulfide bonds), variable fragment (Fv), single chain variable fragment (scFv), bi-specific single-chain variable fragment (bi-scFv), nanobodies, unibodies and diabodies. “Antibody fragments” comprise a portion of an intact antibody, preferably the antigen-binding region or variable region of the intact antibody. Typically, an “antibody” refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The well-known immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively. A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, with each pair having one “light” chain (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains, respectively. According to embodiments of the present disclosure, the antibody fragment can be produced by modifying the nature antibody or by de novo synthesis using recombinant DNA methodologies. In certain embodiments of the present disclosure, the antibody and/or antibody fragment can be bispecific, and can be in various configurations. For example, bispecific antibodies may comprise two different antigen binding sites (variable regions). In various embodiments, bispecific antibodies can be produced by hybridoma technique or recombinant DNA technique. In certain embodiments, bispecific antibodies have binding specificities for at least two different epitopes.
- The term “specifically binds” as used herein, refers to the ability of an antibody or an antigen-binding fragment thereof, to bind to an antigen with a dissociation constant (Kd) of no more than about 1×10−6 M, 1×10−7 M, 1×10−8 M, 1×10−9 M, 1×10−10 M, 1×10−11 M, 1×10−12 M, and/or to bind to an antigen with an affinity that is at least two-folds greater than its affinity to a nonspecific antigen.
- The term “treatment” as used herein includes preventative (e.g., prophylactic), curative or palliative treatment; and “treating” as used herein also includes preventative (e.g., prophylactic), curative or palliative treatment. In particular, the term “treating” as used herein refers to the application or administration of the present molecular construct or a pharmaceutical composition comprising the same to a subject, who has a medical condition a symptom associated with the medical condition, a disease or disorder secondary to the medical condition, or a predisposition toward the medical condition, with the purpose to partially or completely alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of said particular disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition, and/or to a subject who exhibits only early signs of a disease, disorder and/or condition, for the purpose of decreasing the risk of developing pathology associated with the disease, disorder and/or condition.
- The term “effective amount” as used herein refers to the quantity of the present molecular construct that is sufficient to yield a desired therapeutic response. An effective amount of an agent is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered or prevented, or the disease or condition symptoms are ameliorated. The effective amount may be divided into one, two, or more doses in a suitable form to be administered at one, two or more times throughout a designated time period. The specific effective or sufficient amount will vary with such factors as particular condition being treated, the physical condition of the patient (e.g., the patient's body mass, age, or gender), the type of subject being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives. Effective amount may be expressed, for example, as the total mass of active component (e.g., in grams, milligrams or micrograms) or a ratio of mass of active component to body mass, e.g., as milligrams per kilogram (mg/kg).
- The terms “application” and “administration” are used interchangeably herein to mean the application of a molecular construct or a pharmaceutical composition of the present invention to a subject in need of a treatment thereof.
- The terms “subject” and “patient” are used interchangeably herein and are intended to mean an animal including the human species that is treatable by the molecular construct, pharmaceutical composition, and/or method of the present invention. The term “subject” or “patient” intended to refer to both the male and female gender unless one gender is specifically indicated. Accordingly, the term “subject” or “patient” comprises any mammal, which may benefit from the treatment method of the present disclosure. Examples of a “subject” or “patient” include, but are not limited to, a human, rat; mouse; guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl. In an exemplary embodiment, the patient is a human. The term “mammal” refers to all members of the class Mammalia, including humans, primates, domestic and farm animals, such as rabbit, pig, sheep, and cattle; as well as zoo, sports or pet animals; and rodents, such as mouse and rat. The term “non-human mammal” refers to all members of the class Mammalis except human.
- The present disclosure is based, at least on the construction of the T-E pharmaceuticals that can be delivered to target cells, target tissues or organs at increased proportions relative to the blood circulation, lymphoid system, and other cells, tissues or organs. When this is achieved, the therapeutic effect of the pharmaceuticals is increased, while the scope and severity of the side effects and toxicity is decreased. It is also possible that a therapeutic effector is administered at a lower dosage in the form of a T-E molecule, than in a form without a targeting component. Therefore, the therapeutic effector can be administered at lower dosages without losing potency, while lowering side effects and toxicity.
- Diseases that can Benefit from Better Drug Targeting
- Drugs used for many diseases can be improved for better efficacy and safety, if they can be targeted to the disease sites, i.e., if they can be localized or partitioned to the disease sites more favorably than the normal tissues or organs. Certain antibody drugs, which target infectious microorganisms or their toxic products, can be improved, if they are empowered with the ability to recruit immunocytes, which phagocytose and clear the antibody-bound particles. Following are primary examples of diseases, in which drugs can be improved if they can be preferentially distributed to the disease sites or cells or if they can recruit phagocytic immunocytes.
- I Central Nervous System Diseases
- For treating diseases of the central nervous system (CNS), the therapeutic agents are often required to pass through the blood-brain barrier (BBB) to get into the CNS. Some therapeutic agents do not get into the CNS; they regulate certain activities, such as immune activities, in the peripheral, which then modulates the diseased conditions in the CNS. The BBB is formed by the endothelial cells lining the capillaries of blood vessels in the CNS. Unlike the capillaries in the peripheral tissues and organs, the capillary endothelial cells in the BBB are connected by tight junctions formed by occludin, claudins, and junctional adhesion molecules.
- At least six antibodies, namely, aducanumab, bapinerumab, crenezumab, gantenerumab, ponezumab, and solanezumab, specific for β-amyloid, which is responsible for causing Alzheimer's disease, have been developed and placed in clinical development. These antibodies generally fall short of satisfactory therapeutic efficacy in improving Alzheimer's disease. A general belief is that if those antibodies are to achieve therapeutic efficacy, a significant portion must get across the BBB to enter the injured sites in the CNS. However, only very minute portions of those antibodies get across the BBB.
- Interferon-β-1a (IFN-β-1a) and interferon-β-1b (IFN-β-1b) have been used for the treatment of multiple sclerosis (MS). The pharmaceuticals, IFN-β-1a produced by mammalian cells and IFN-β-1b produced in E. coli, are one-chain protein of 166 amino acid residues containing one disulfide bond. It has been claimed that those therapeutic agents reduce relapse of MS in 18-38% of treated patients. The mechanisms of action of IFN-β-1a and IFN-β-1b are very complex and not completely understood, involving the increased generation of anti-inflammatory immune cells and factors and the down-regulation of pro-inflammatory cells and factors. IFN-β treatment in MS patients also reduces the trafficking of pro-inflammatory T cells across the BBB. It is yet unanswered whether IFN-β-1a and IFN-β-1b mediate their pharmacologic effects in part by getting into the injured sites in the CNS.
- When an antibody or protein therapeutic is administered in the body's peripheral, only a very minute amount (about 0.1%) reaches to the CNS, because only a very minute portion of the protein therapeutic gets across the BBB. However, it has also been found that in many diseases of the CNS, including Alzheimer's disease and multiple sclerosis, the inflammation at the diseased sites renders the BBB to breakdown, leading to increased permeability. Therefore, we rationalize that if a larger proportion of an administered antibody specific for β-amyloid or IFN-β-1a and IFN-β-1b is channeled to the BBB, a higher percentage of the therapeutic agents can pass through the BBB and better therapeutic effects can be achieved.
- Furthermore, some therapeutic agents have been developed to inhibit the entry of inflammatory immunocytes to across the BBB. A notable example is natalizumab specific for the cell adhesion molecule integrin α4. The antibody functions by inhibiting inflammatory immune cells to attach to and pass through the epithelial layer lining the BBB. While natalizumab has been shown to be therapeutic efficacious, it has serious immunosuppressive side effect. In particular, it causes progressive multifocal leukoencephalopathy, an opportunistic infection caused by John Cunningham virus (JC virus). We therefor rationalize that if a larger proportion of an antibody specific for integrin α4 is recruited to the BBB, a smaller dose will be required, better therapeutic effects can be achieved, and fewer side effects will occur.
- The endothelial cells in the capillaries forming the BBB express transferrin receptors and insulin receptors, which mediate the transcytosis of transferrin and insulin molecules, respectively, to the cerebral parenchyma. For using the transferrin receptor as a ferry, only a small proportion gets through while the reaming bulk are trapped or degraded. Because the endothelial cells lining the capillaries in other parts of the vasculature do not express transferrin receptors, the transferrin receptors on the endothelial cells in the BBB can serve as site-specific antigen for recruiting administered therapeutics. Once the therapeutic is concentrated in the BBB, an increased proportion of it will pass through the capillaries.
- We also rationalize that when the mechanisms for channeling pharmaceuticals to the BBB is established, anti-inflammatory drugs, such as anti-TNF-α, anti-IL12/IL-23, anti-IL17, and anti-CD3, should be investigated for their therapeutic effects on many types of diseases of the CNS.
- For the antibody therapeutic specific for integrin α4, the transferrin receptor is used as a target site recruiter. For Alzheimer disease, the effector moiety can be a few copies of scFv specific for β-amyloid; for treating multiple sclerosis, the effector moiety can be a few copies of IFN-β-1a or IFN-β-1b, or a few copies of scFv specific for integrin α4.
- Embodiments of the present disclosure disclose several T-E molecules respectively exist in single multi-arm linker-units or joint-linker configurations, each contains scFv specific for transferrin receptor as the targeting element and IFN-β-1a or IFN-β-1b or scFv specific for integrin α-4 as the effector element. Alternative embodiments disclose T-E molecules respectively exist in single linker-units or joint-linker configurations, each contains scFv specific for transferrin receptor as the targeting element and scFv specific for β-amyloid as the effector element.
- Fingolimod is an immunosuppressive drug that is derived from a natural product myriocin originally isolated from certain fungi. Fingolimod has been approved for reducing the relapse of relapsing-remitting multiple sclerosis. Fingolimod is phosphorylated in vivo to form fingolimod-phosphate, which resembles naturally occurring sphingosine-1-phosphate (S1P), an extracellular lipid mediator, and can bind to 4 of the 5 S1P receptors. The S1P receptors are expressed on lymphocytes and involved in lymphocyte migration. A generally pharmacologic mechanism of fingolimod is that it inhibits lymphocytes egress from the lymphoid tissues to the circulation and hence to the CNS. Fingolimod can cross BBB to enter CNS and many cell types in the CNS express S1P receptors, which play roles in cell proliferation, morphology, and migration. It is believed that fingolimod can have direct on the CNS. The administration of fingolimod causes common side effects of headache and fatigue, and severe side effects of skin cancer, macular edema, and fatal infections, such as hemorrhaging focal encephalitis.
- A fingolimod molecule has an NH2 group and thus provides a functional group to couple with a bi-functional linker with an NHS group. One preferred embodiment of the present invention is to prepare a T-E construct, which contains a targeting element for delivery to the BBB and a drug bundle of fingolimod as an effector element. For a bundle of fingolimod, 5-10 molecules are incorporated to a linker unit, using either a cleavable linker or non-cleavable linker to conjugate fingolimod molecules to the linking arms of a linker unit. Since fingolimod, after uptake in a patient, is modified to fingolimod phosphate to resemble sphingosine1-phosphate and become active, the drug bundle is alternatively prepared with fingolimod phosphate. A linker unit with fingolimod or fingolimod phosphate bundle is conjugated with 1 or 2 scFv specific for a transferrin receptor I. Upon administration of the molecular construct, a portion of it is carried to the BBB. The fingolimod molecules released from the cleavable linkers pass through the BBB and enter the CNS. Or, a portion of the entire construct enters the CNS. Cleavable linkers can be designed by employing a number of cleaving mechanisms. An installment of S—S bond is often used, since S—S disulfide bond can be cleaved by a reduction reaction at the target tissue site. A peptide bond between amino acids, which is sensitive to proteases, such as matrix metalloproteinases in many tissues and cathepsins in endosomes in target cells, is also commonly used as a cleavable bond in many linker designs.
- II Infectious Disease
- Although large numbers of monoclonal antibodies have been made against components of a various viruses, bacteria, and fungi, which cause serious infectious in humans and animals, few monoclonal antibodies have been developed into preventive treatments or therapeutic agents to counter infections. These shortcomings can be attributed to a few major factors. One major factor is the infectious microorganisms and their products have different serotypes and variable reactivity toward a particular antibody. Another reason is that the targeted microorganisms undergo mutations and escape the targeting of a particular antibody.
- The T-E molecular design of the present invention can also be applied for the prevention and treatment of infectious diseases. The plurality of the linking arms can enhance the avidity and specificity of binding to target infectious microorganisms or their products and elicit immune functions to facilitate the clearance of the microorganisms and their products. We reason that the avidity enhancement and the recruitment of immune clearance function can somehow overcome the serotypic difference and mutational problems. Such improvements should increase the efficacy of the candidate antibodies for the prevention and therapy of infectious diseases. Many antibodies, which have failed to meet expectation in clinical trials, may be configured with the present invention and re-investigated.
- A preferred set of embodiment of the present invention is to employ joint-linkers configuration with one linker-unit for targeting and one linker-unit for recruiting effector function. An alternative set of preferred embodiment is to employ single linker-units with multiple linking arms for targeting elements and a coupling arm for an effector element. The targeting elements may be one of the two categories: (1) scFv or sdAb specific for a surface component of a microorganism or its product, e.g., envelope protein gp120 of human immunodeficiency virus type 1 (HIV-1), F protein of respiratory syncytia virus (RSV), a surface antigen of Clostridium difficile or Staphylococcus aureus, or endotoxin of Gram-negative bacteria or Shiga-like toxin of Escherichia coli, or (2) the extracellular portions of cell surface receptors of viruses, such as the HIV-1 gp120-binding CD4 domain.
- The effector elements are 1 or 2 scFv or sdAb specific for one Fc receptor of IgG, e.g. FcγRIIA (CD32), FcγRIIIB (CD16b), or FcγRI (CD64). Those receptors are expressed on neutrophils, macrophages, and eosinophils and are the key molecules mediating phagocytosis of antibody-bound microorganisms. FcγRIIA and FcγRIIIB bind to IgG with low affinity (Kd in the range of 10−6 to 10−7), and FcγRI binds to IgG1 and IgG3 with high affinity (Kd 10−9). It is advantageous to employ scFv or sdAb specific for FcγRIIA or FcγRIIIB, because they can compete favorably with IgG in binding to the receptors.
- The antibodies specific for carbohydrate antigens on bacterial surface are usually weak in binding affinity and are expressed in IgM rather than IgG. An IgM molecule has 10 Fv's (antigen-binding sites). However, an IgM molecule, which has a molecular weight of about 1000 kd, cannot cross capillaries and reach to extravascular space. With the configuration of the present invention, a molecular construct carrying 6 scFv or 10 sdAb will have a molecular weight of about 150 kd.
- In employing antibody-based therapeutics for clearing viruses, it is important that the therapeutic does not lead to FcR-mediated enhancement of viral infection. In those cases, the bound viral particles are not phagocytosed and digested. Some viruses, such as Dengue virus can multiply in phagocytes. Thus, if the viral particles gain access to a cell and enter the bound cells without being destroyed, the virus can multiply in the infected cells. Therefore, a set of preferred embodiments of this invention is that the molecular construct contains 2 or more scFv specific for an Fcγ receptor and can bind to multiple Fcγ receptor molecules on phagocyte cell surface, so that the bound viral particles are destined to phagocytosis pathway.
- Among the many antibodies specific for viruses, bacteria, or their products, which have been in clinical trials, only antibodies specific for RSV have been approved for clinical uses. Even for antibodies against RSV, they are only approved for prevention, and not for treatment of on-going infection. It is desirable that an anti-RSV antibody can be developed for treating already-infected subjects. The other antibodies are still in clinical development or have failed in clinical trials. With the molecular construct platforms of this invention, all of these antibodies can be employed for improved efficacy. A partial list of those antibodies are:
-
- (1) Palivizumab and felvizumab specific for RSV F protein
- (2) Suvizumab specific for HIV-1 gp120
- (3) Libivirumab, exbivirumab, tuvirumab specific for hepatitis B surface antigen (HBsAg) of HBV
- (4) CR6261 mAb, diridavumab, and firivumab specific for hemagglutinin A of influenza A virus
- (5) Regavirumab and sevirumab specific for glycoprotein of cytomegalovirus
- (6) Rafivirumab specific for glycoprotein of rabies virus
- (7) Actoxumab and bezlotoxumab specific for surface antigen of Clostridium difficile
- (8) Obiltoxaximab and raxibacumab specific for Bacillus anthracis anthrax
- (9) Panobacumab (human IgM monoclonal antibody) specific for Pseudomonas aeruginosa serotype IATS O11
- (10) Tefibazumab and tosatoxumab specific for clumping factor A of Staphylococcus aureus
- (11) Edobacomab specific for endotoxin of Gram-negative bacteria for treating sepsis
- (12) Pagibaximab specific for lipoteichoic acid of staphylococcus aureus for treating staphylococcal sepsis
- (13) Raxibacumab (human monoclonal antibody) specific anthrax toxin
- (14) Pritoxaximab, setoxaximab, and urtoxazumab specific for Shiga-like toxin type I or II of Escherichia coli.
- Fc-Based Molecular Constructs for Treating Central Nervous System Diseases or Infectious Diseases
- In the broad sense of the Fc-based configuration, immunoglobulin antibody can serve as the base of a targeting or effector element, and its corresponding effector or targeting element can be incorporated at the C-terminal of its two heavy γ chains in the form of scFv domains. For a typical “Fc-based” configuration, two-chain IgG.Fc is used as the base of the molecular platform. Each of the polypeptide chain is fused with one or two targeting and one or two effector elements, for a total of two to three elements on each chain. The T-E molecule with an Fc-based configuration will have a total of four to six elements (e.g., scFv or any other antibody fragments). Optionally, the Fc portion of the molecular constructs also carries Fc-mediated effector functions, ADCC, and/or complement-mediated activation. While in certain other applications, such Fc-mediated effector functions are avoided.
- In designing the Fc-based molecular constructs, targeting elements are positioned at the N- or C-terminus. If the effector elements function by binding to a cell surface component, they should also be positioned at the terminus. If the effector elements function by binding to and neutralizing soluble factors, they can be positioned between a terminal targeting or effector element and CH2-CH3.
- By selecting the T-E elements of the present Fc-based molecular construct, the molecular construct can be used to treat central nervous system (CNS) diseases or infectious diseases. The present disclosure is also advantageous in that, in some embodiments, it utilizes the linker unit according to the first aspect of the present disclosure, which provides a facile means for controlling the number of the targeting and effector elements of the present Fc-based molecular constructs. Depending on the targeting and/or effector elements selected, the present Fc-based molecular construct may take different configurations, which are discussed below, respectively.
- In the present Fc-based molecular constructs, both the targeting element and effector element are antibodies or fragments thereof.
- Referring to
FIG. 1A , which is a schematic diagram illustrating an Fc-basedmolecular construct 800A according to certain embodiments of the present disclosure. As illustrated, the Fc-basedmolecular construct 800A comprises two identical CH2-CH3 chains 810, a pair of effector elements E1 linked to the N-termini of the CH2-CH3 chains 810, and a pair of targeting elements T1 linked to the C-termini of the CH2-CH3 chains 810. In this illustrative configuration, both the targeting element T1 and effector element E1 are scFvs. - The Fc-based
molecular construct 800B illustrated inFIG. 1B is quite similar to the Fc-basedmolecular construct 800A ofFIG. 1A in structure, except that the two effector elements E1 are respectively linked to the C-termini of the CH2-CH3 chains 810, while the two targeting effectors are respectively linked to the C-termini of the CH2-CH3 chains 810. - According to certain embodiments, both the effector elements and targeting elements are linked to the N-termini of the CH2-CH3 chains. For example, when both the effector element and the targeting element are in the form of single-chain variable fragments (scFvs), the effector element and the targeting element may be linked in a tandem or diabody configuration, thereby forming a bispecific scFv that is linked to the N-terminus of the CH2-CH3 chain.
- The Fc-based
molecular construct 800C (FIG. 1C ) comprises an Fc portion, and accordingly, each CH2-CH3 chain 810 has a T1-E1 bispecific scFv linked to the N-terminus thereof. - In some examples, the pair of effector elements or the pair of the targeting elements takes a Fab configuration (i.e., consisting of the VH-CH1 domain and the VL-Cκ domain); this Fab fragment is linked to the N-termini of the CH2-CH3 chains, so that the Fc-based molecular construct adopts an IgG configuration. In these cases, the pair of elements that is not in the Fab configuration may be linked to the C-termini of the pair of CH2-CH3 segments.
- For example, in the Fc-based
molecular construct 900 ofFIG. 2 , each of the two targeting elements T1 comprises the VH-CH1 domain 820 and the VL-Cκ domain 825, thereby forming aFab configuration 830 that is linked to the N-termini of the CH2-CH3 chains 810, so that the Fc-basedmolecular construct 900 adopts the IgG configuration. In this case, the pair of effector elements E1 is linked to the C-termini of the pair of CH2-CH3 chains 810. - According to some embodiments, the present Fc-based molecular construct has an effector element which is a peptide.
- For example, according to certain embodiments of the present disclosure, the effector element can be a peptide with certain therapeutic effect, while the targeting element is an antibody or a fragment thereof (see,
FIGS. 3A and 3B ). As illustrated, the Fc-basedmolecular construct 1000A ofFIG. 3A comprises a pair of targeting elements T1 (as scFvs) linked to the N-termini of the pair of CH2-CH3 segments 1210, and a pair of effector elements E1 (in the form of therapeutic peptides) linked to the C-termini of the pair of CH2-CH3 segments 1210. - Similarly, in the Fc-based
molecular construct 1000B ofFIG. 3B , the pair of targeting elements T1 (as scFvs) is linked to the C-termini of the pair of CH2-CH3 segments 1210, whereas the pair of effector elements E1 (in the form of therapeutic peptides) is linked to the C-termini of the pair of CH2-CH3 segments 1210. - As could be appreciated, for Fc-base molecular constructs that use a peptide as the effector element, the targeting element can be constructed into a Fab fragment, so that the molecular constructs take the IgG configuration.
- In the configuration illustrated in
FIGS. 1A to 3B , the CH2-CH3 chains are adopted from human immunoglobulins γ1 or γ4. In general, γ1 is chosen, when Fc-mediated functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated activity (inflammatory activation or target cell lysis), are desired. In the case where Fc-mediated functions are avoided, γ4 is chosen for constructing the present Fc-based molecular constructs. - Functional Elements Suitable for Use with Fc-Based Molecular Construct
- Now that the basic structural arrangements of the Fc-based molecular constructs have been discussed above, certain combinations of particular effector element(s) and targeting element(s) are provided below for the illustration purpose.
- To treat central nervous system (CNS) diseases, an antibody (or a fragment thereof) specific for transferrin receptor can be used as the targeting element, in connection with effector elements suitable for the particular CNS disease. For example, Fc-based molecular constructs for the treatment of multiple sclerosis may use an scFv specific for integrin-α4 as the effector element. In the case of Alzheimer's disease, illustrative Fc-based molecular constructs can use an scFv specific for β-amyloid as the effector element. The above-mentioned Fc-based molecular constructs for treating CNS diseases may take the configuration described in connection with any of
FIGS. 1A to 1C , andFIG. 2 . - Fc-based molecular constructs for treating multiple sclerosis may also use INF-β1a or INF-β1b as the effector elements. In this case, the Fc-based molecular constructs may take the configuration described in connection with
FIG. 3A or 3B . - In constructing Fc-based molecular constructs for treating diseases/conditions associated with infection (such as viral infections or bacterial infections), one may use an antibody (or a fragment thereof) specific for a viral protein or bacterial protein as the targeting element. As to the effector elements for treating infections, an antibody (or a fragment thereof) specific for CD32 or CD16b can be used. These Fc-based molecular constructs may take the configuration described in connection with any of
FIGS. 1A to 1C , andFIG. 2 . - The essence of this invention is the rationalization and conception of the specific combination or pairing of the targeting and effector elements. The adoption of Fc-fusion configuration in the molecular constructs is a preferred embodiment. It is conceivable for those skilled in the arts to link the pairs of targeting and effector elements of this invention employing other molecular platforms, such as peptides, proteins (e.g., albumin), polysaccharides, polyethylene glycol, and other types of polymers, which serve as a structural base for attaching multiple molecular elements.
- III-(iii) Use of Fc-Based Molecular Construct
- The present disclosure also pertains to method for treating CNS diseases using the suitable Fc-based molecular construct. Generally, the method comprises the step of administering to a subject in need of such treatment an effective amount of the Fc-based molecular construct according to embodiments of the present disclosure.
- The present disclosure further pertains to method for treating infections using the suitable Fc-based molecular construct. Generally, the method comprises the step of administering to a subject in need of such treatment an effective amount of the Fc-based molecular construct according to embodiments of the present disclosure.
- The scFv1-CH2-CH3-scFv2 (human γ1) recombinant chain was configured by fusing two scFvs, in which the first one specific for Protein F of RSV fused to the N-terminal of CH2 domain of IgG1.Fc through a flexible hinge region, while the second one specific for ectodomain of CD32a was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS)3.
- Both of the scFvs had an orientation of VL-linker-VH. The VL and VH in each of the two scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG. The sequence of the recombinant chain in the IgG1.Fc fusion protein molecular construct is shown as SEQ ID NO: 1.
- Illustrated below is the configuration of the prepared 2-chain (scFv α RSV)-(scFv α CD32a)-hIgG1.Fc molecular construct.
- In this Example, the gene-encoding sequence was placed in pcDNA3 expression cassette. Expi293F cells were seeded at a density of 2.0×106 viable cells/ml in Expi293F expression medium and maintained for 18 to 24 hours prior to transfection to ensure that the cells were actively dividing at the time of transfection. At the time of transfection, 7.5×108 cells in 255-ml medium in a 2-liter Erlenmeyer shaker flask were transfected by ExpiFectamine™ 293 transfection reagent. The transfected cells were incubated at 37° C. for 16 to 18 hours post-transfection in an orbital shaker (125 rpm) and the cells were added ExpiFectamine™ 293 transfection enhancer 1 and enhancer 2 to the shaker flask, and incubated for 7 days. Culture supernatants were harvested and recombinant 2-chain (scFv α RSV)-hIgG1.Fc-(scFv α CD32a) fusion protein in the media was purified using Protein A chromatography. Following buffer exchange to PBS, the concentration of (scFv α RSV)-hIgG1.Fc-(scFv α CD32a) protein was determined and analyzed by 12% SDS-PAGE shown in
FIG. 4A . The Fc-fusion molecular construct was revealed as the major band at about 85 kDa, consistent with the expected size. - To examine the binding ability of recombinant 2-chain (scFv α RSV)-hIgG1.Fc-(scFv α CD32a) fusion protein to both Protein F of RSV and ectodomain of CD32a, ELISA assay was performed. ELISA plates were coated with 2 μg/mL of Protein F of RSV (Sino biological Inc.). Recombinant 2-chain (scFv α RSV)-hIgG1.Fc-(scFv α CD32a) fusion protein and (scFv α RSV)-hIgG1.Fc were detected by HRP-conjugated goat anti-human IgG1.Fc. The ELISA results in
FIG. 4B show that the recombinant 2-chain (scFv α RSV)-hIgG1.Fc-(scFv α CD32a) fusion protein bind to Protein F of RSV, using adalimumab scFv as a control scFv. -
FIG. 4C shows binding activity of the recombinant Fc-fusion protein to ectodomain of CD32a. ELISA plates were coated with 5 μg/mL of recombinant ectodomain of CD32a. Recombinant 2-chain (scFv α RSV)-hIgG1.Fc-(scFv α CD32a) fusion protein was detected by HRP-conjugated goat anti-human IgG1.Fc.FIG. 4C shows that the recombinant 2-chain (scFv α RSV)-hIgG1.Fc-(scFv α CD32a) Fc-fusion protein has binding activity to recombinant ectodomain of CD32a. Recombinant 2-chain (scFv α endotoxin)-IgG1.Fc protein was used as a control antibody. - The scFv1-CH2-CH3-scFv2 (human γ1) recombinant chain was configured by fusing two scFvs, in which the first one specific for endotoxin was fused to the N-terminal of CH2 domain of IgG1.Fc through a flexible hinge region, and the second one specific for ectodomain was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS)3.
- Both of the scFvs had an orientation of VL-linker-VH. The VL and VH in each of the two scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG.
- The sequence of the recombinant chain in the IgG1.Fc fusion protein molecular construct is shown as SEQ ID NO: 2. The expression of the constructed gene in Expi293F cells and the purification of the expressed fusion protein were performed as in preceding Examples. Characterization of the new construct was performed with SDS-PAGE and ELISA. The SDA-PAGE results in
FIG. 5A shows that the recombinant chain of the new construct has a size of about 85 kDa, consistent with the expected size. -
FIG. 5B shows ELISA results of the recombinant 2-chain (scFv α endotoxin)-(scFv α CD32a)-hIgG1.Fc binding to E. coli LPS 0111:B4 (Sigma Aldrich). ELISA plates were coated with 50 μg/ml poly-L-lysine. Subsequently, the poly-L-lysine-coated plates were further coated with 10 μg/ml E. coli LPS 0111:B4. The recombinant fusion protein was detected by HRP-conjugated goat anti-human IgG.Fc. The ELISA results show that the present recombinant Fc-fusion protein has binding activity to E. coli LPS 0111:B4 (Sigma Aldrich);FIG. 5C shows that the recombinant Fc-fusion protein has binding activity to ectodomain of CD32a. - Illustrated below is the configuration of the thus-prepared 2-chain (scFv α endotoxin)-(scFv α CD32)-hIgG1.Fc molecular construct.
- The 2-chain IgG.Fc fusion protein was prepared by configuring (interferon-β-1a)-CH2-CH3-(scFv α TfR1) (human γ4) in a recombinant chain. The C-terminal of the interferon-β-1a was fused to the N-terminal of CH2 via a linker, GGGGSGGGASGGS. The scFv specific for ectodomain of TfR1 was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS)3.
- The scFv (specific for ectodomain of TfR1) had an orientation of VL-linker-VH. The VL and VH in the scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG. The sequence of the recombinant chain in the IgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 3.
- Illustrated herein is the configuration of the prepared 2-chain (interferon-β-1a)-IgG4.Fc-(scFv α TfR1) molecular construct.
- In this Example, the gene-encoding sequence was placed in pcDNA3 expression cassette. Expi293F cells were seeded at a density of 2.0×106 viable cells/ml in Expi293F expression medium and maintained for 18 to 24 hours prior to transfection to ensure that the cells were actively dividing at the time of transfection. At the time of transfection, 7.5×108 cells in 255-ml medium in a 2-liter Erlenmeyer shaker flask were transfected by ExpiFectamine™ 293 transfection reagent. The transfected cells were incubated at 37° C. for 16 to 18 hours post-transfection in an orbital shaker (125 rpm) and the cells were added ExpiFectamine™ 293 transfection enhancer 1 and enhancer 2 to the shaker flask, and incubated for 7 days. Culture supernatants were harvested and recombinant 2-chain (Interferon-β-1a)-hIgG1.Fc-(scFv α TfR1) fusion protein in the media was purified using Protein A chromatography. Following buffer exchange to PBS, the concentration of (Interferon-β-1a)-hIgG1.Fc-(scFv α TfR1) protein was determined and analyzed by 8% SDS-PAGE shown in
FIG. 6A . The Fc-fusion molecular construct was revealed as the major band at about 80 kDa, consistent with the expected size. - Binding activity of recombinant (Interferon-β-1a)-hIgG1.Fc-(scFv α TfR1) was assayed by ELISA using a 96-well plate coated with recombinant (Interferon-β-1a)-hIgG1.Fc-(scFv α TfR1) protein in 5μg/ml concentration, 100 μl per well. The scFv specific for ectodomain of TfR1 is as a negative control. Recombinant 2-chain (Interferon-β-1a)-hIgG1.Fc-(scFv α TfR1) was detected by HRP-conjugated rabbit anti-human interferon-β polyclonal antibody (Santa Cruz Biotechnology, Dallas, USA). Next, 50 μl of TMB substrate was added for color development. The reaction was stopped by 50 μl of 1M HCl. Absorbance at 450 nm was measured with a plate reader, Each bar represents the mean OD450 value of duplicate samples.
-
FIG. 6B shows ELISA analysis of the present the molecular construct. The ELISA results show that (Interferon-β-1a)-hIgG1.Fc-(scFv α TfR1) fusion protein bound specifically to recombinant ectodomain of TfR1 protein. - The VL and VH of the scFv specific for integrin α4 were from monoclonal antibody natalizumab. The 2-chain IgG.Fc fusion protein was prepared by configuring (scFv α integrin α4)-CH2-CH3-(scFv α TfR1) (human γ4) in a recombinant chain. The C-terminal of the scFv specific for integrin α4 was fused to the N-terminal of CH2 via a linker, GGGGSGGGASGGS. The scFv specific for ectodomain of TfR1 was fused to the C-terminal of CH3 domain through a flexible linker, (GGGGS)3. The result of 8% SDA-PAGE in
FIG. 7A shows that the recombinant chain of the new construct has a size of about 85 kDa (indicated by arrow), consistent with the expected size. - The two scFv had the orientation of VL-linker-VH. The VL and VH in each of the two scFv were connected by a hydrophilic linker, GSTSGSGKPGSGEGSTKG. The sequence of the recombinant chain in the IgG4.Fc fusion protein molecular construct is shown as SEQ ID NO: 4.
- Illustrated herein is the configuration of the prepared 2-chain (scFv α integrin α4)-IgG4.Fc-(scFv α TfR1) molecular construct.
- To examine the binding ability of recombinant 2-chain (scFv α integrin α4)-IgG4.Fc-(scFv α TfR1) protein to integrin α4-expressing Jurkat T cells, cell-binding assay was performed by flow cytometry.
- 1×106 Jurkat T cells was maintained in the RPMI1640 medium supplemented with 10% FBS at a density of 1×105. The cells were kept in 37° C. with 5% CO2 in a humidified chamber. 1×106 Jurkat T cells were washed with the binding buffer (phosphate-buffered saline with 0.1% FBS, 2 mM EDTA and 20 ng/ml NaN3) twice. 10 μg/ml of Human BD Fc Block™ (BD Biosciences, San Jose, US) was added to the washed Jurkat T cells to block Fc receptor mediated. Cells were washed and incubated with 10 μg/ml of recombinant (scFv α integrin α4)-IgG4.Fc-(scFv α TfR1) protein on ice for 15 minutes, using recombinant 2-chain (interferon-β-1a)-IgG4.Fc-(scFv α TfR1) as a negative control. Cells were washed again and incubated with FITC-conjugated goat anti-human IgG.Fc (Caltag, Buckingham, UK), diluted 1:200 in blocking buffer, at on ice for 15 min in the dark. The stained cells were analyzed on a FACSCanto II flow cytometer (BD Biosciences).
-
FIG. 7B shows results of the cell staining analysis of recombinant 2-chain (scFv α integrin α4)-IgG4.Fc-(scFv α TfR1) protein on integrin α4-expressing Jurkat T cells. The construct bound to Jurkat T cells substantially positively. - To test the effects of recombinant 2-chain (scFv α endotoxin)-hIgG1.Fc-(scFv α CD32a) fusion protein on inhibiting TNF-α secretion, ELISA was to determine the amount of secreted TNF-α in the supernatant by macrophage-like U937 cells.
- U937 cells were maintained in RPMI1640 supplemented with 10% fetal bovine serum (Gibco) and 100 U/ml penicillin-streptomycin (Gibco), at the density between 3×105 and 2×106 cells/ml. The cells were kept in 37° C. with 5% CO2 in a humidified chamber. To differentiate U937 into macrophage-like cells, 1×106 cells/ml of U937 were incubated with 10 ng/ml of phorbol 12-myristate β-acetate (PMA, Sigma Aldrich). After 48 hours, non-adherent cells were removed, and adherent cells were washed and seeded into 96-well plates.
- 5×104 cells/well of differentiated 0937 were seeded into 96-well plates the day before assay. Cells were stimulated with 1 μg/ml E. coli LPS 0111:B4 (Sigma Aldrich) alone, or premixes of LPS and 10 μg/ml of (scFv α endotoxin)-hIgG1Fc, 15 μg/ml of (scFv α endotoxin)-hIgG1 Fc-(scFv α CD32a) or 2.5 μg/ml of anti-CD32a scFv. The stimulation proceeded for 2 hours before the supernatant was collected. TNF-α production was measured by commercially available ELISA kit (Biolegend).
- TNF-α levels in U937 supernatant were measured using an ELISA kit from R&D Systems. The wells of ELISA plates (Greiner Bio-One) were coated with 4 μg/mL of capture antibody in PBS at 4° C. overnight. Wells were subsequently blocked by 0.5% in PBS for 1 hour and incubated with diluted culture supernatant for 2 hours. 400 ng/mL of biotin-labeled detection antibody was used followed by Streptavidin-HRP to detect bound TNF-α. Chromogenic reaction was carried out using TMB substrate (Clinical Science Products), and stopped by adding 1N HCl. Plates were read at 450 nm absorbance. Concentrations of TNF-α were determined by extrapolation from four-parameter logistic fit standard curves generated from dilutions of standard protein supplied by the manufacturer.
-
FIG. 8 shows that recombinant 2-chain (scFv α endotoxin)-hIgG1 Fc-(scFv α CD32a) significantly reduced TNF-α secretion stimulated by E. coli LPS 0111:B4, compared to control antibodies 2-chain (scFv α endotoxin)-hIgG1 Fc protein and anti-CD32a scFv or medium alone. - It will be understood that the above description of embodiments is given by way of example only and that various modifications may be made by those with ordinary skill in the art. The above specification, examples and data provide a complete description of the structure and use of exemplary embodiments of the invention. Although various embodiments of the invention have been described above with a certain degree of particularity, or with reference to one or more individual embodiments, those with ordinary skill in the art could make numerous alterations to the disclosed embodiments without departing from the spirit or scope of this invention.
Claims (8)
1. A molecular construct comprising,
a pair of CH2-CH3 segments of an IgG.Fc;
a pair of effector elements, wherein each effector element is interferon β1a (INF-β1a) or INF-β1b, or an antibody fragment specific for integrin α4 or β-amyloid; and
a pair of targeting elements, wherein each targeting element is an antibody fragment specific for human transferrin receptor or human insulin receptor, wherein,
when the pair of effector elements is linked to the N-termini of the pair of CH2-CH3 segments, then the pair of targeting elements is linked to the C-termini of the pair of CH2-CH3 segments, and vice versa, or
when the pair of effector elements and the pair of targeting elements are both in the form of single-chain variable fragments (scFvs), then the pair of targeting elements is linked to the N-termini of the pair of effector elements in a tandem or diabody configuration, thereby forming a pair of bispecific scFvs that are linked to the N-termini of the pair of CH2-CH3 segments.
2. The molecular construct of claim 1 , wherein the pair of CH2-CH3 segments is derived from human γ1 or γ4 immunoglobulin.
3. The molecular construct of claim 1 , wherein when the pair of effector elements is in the form of an antigen-binding fragment (Fab), and the pair of targeting elements is in the form of scFvs, and vice versa; then the Fab and scFvs are respectively linked to the N-termini and C-termini of the CH2-CH3 segments, so that the molecular construct adopts an extended IgG configuration.
4. The molecular construct of claim 1 , wherein,
the effector element is INF-β1a, INF-β1b, or an scFv specific for integrin α4; and
the targeting element is an scFv specific for human transferrin receptor.
5. The molecular construct of claim 1 , wherein,
the effector element is an scFv specific for β-amyloid; and
the targeting element is an scFv specific for human transferrin receptor.
6. A method for treating a central nervous system (CNS) disease in a subject in need thereof, comprising the step of administering to the subject an effective amount of the molecular construct according to claim 1 .
7. The method of claim 6 , wherein,
the CNS disease is multiple sclerosis;
the pair of CH2-CH3 segments is derived from human γ4 immunoglobulin;
the effector element is INF-β1a, INF-β1b, or an antibody fragment specific for integrin α4; and
the targeting element is an antibody fragment specific for human transferrin receptor.
8. The method of claim 6 , wherein,
the CNS disease is Alzheimer's disease;
the pair of CH2-CH3 segments is derived from human γ4 immunoglobulin;
the effector element is an antibody fragment specific for β-amyloid; and
the targeting element is an antibody fragment specific for human transferrin receptor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/159,862 US20160340435A1 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs for treating central nervous system diseases |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562164400P | 2015-05-20 | 2015-05-20 | |
US201562213012P | 2015-09-01 | 2015-09-01 | |
US14/997,827 US10010626B2 (en) | 2015-01-16 | 2016-01-18 | Molecular constructs with targeting and effector moieties |
US14/997,874 US10668165B2 (en) | 2015-01-16 | 2016-01-18 | Molecular constructs for treating tumors |
US14/997,849 US20170152323A1 (en) | 2015-01-16 | 2016-01-18 | Anti-inflammatory molecules with tissue-targeting functions |
US14/997,764 US9907858B2 (en) | 2015-01-16 | 2016-01-18 | Peptide core-based multi-arm linkers |
US201662308349P | 2016-03-15 | 2016-03-15 | |
US15/159,862 US20160340435A1 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs for treating central nervous system diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/997,764 Continuation US9907858B2 (en) | 2015-01-16 | 2016-01-18 | Peptide core-based multi-arm linkers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160340435A1 true US20160340435A1 (en) | 2016-11-24 |
Family
ID=57318912
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/159,834 Active US10202455B2 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod |
US15/159,829 Active US9988454B2 (en) | 2015-05-20 | 2016-05-20 | Peptide core-based multi-arm linkers for treating central nervous system diseases |
US15/159,863 Abandoned US20160340427A1 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs for treating infectious diseases |
US15/159,862 Abandoned US20160340435A1 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs for treating central nervous system diseases |
US15/159,831 Active 2036-01-22 US9994638B2 (en) | 2015-05-20 | 2016-05-20 | Peptide core-based multi-arm linkers for treating infectious diseases |
US15/159,839 Active US10442861B2 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs with targeting and effector moieties for treating infectious diseases |
US15/159,828 Active US9975951B2 (en) | 2015-05-20 | 2016-05-20 | Peptide core-based multi-arm linkers and their applications |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/159,834 Active US10202455B2 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod |
US15/159,829 Active US9988454B2 (en) | 2015-05-20 | 2016-05-20 | Peptide core-based multi-arm linkers for treating central nervous system diseases |
US15/159,863 Abandoned US20160340427A1 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs for treating infectious diseases |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/159,831 Active 2036-01-22 US9994638B2 (en) | 2015-05-20 | 2016-05-20 | Peptide core-based multi-arm linkers for treating infectious diseases |
US15/159,839 Active US10442861B2 (en) | 2015-05-20 | 2016-05-20 | Molecular constructs with targeting and effector moieties for treating infectious diseases |
US15/159,828 Active US9975951B2 (en) | 2015-05-20 | 2016-05-20 | Peptide core-based multi-arm linkers and their applications |
Country Status (10)
Country | Link |
---|---|
US (7) | US10202455B2 (en) |
EP (1) | EP3297670A4 (en) |
JP (1) | JP6602958B2 (en) |
CN (1) | CN107847588B (en) |
AU (1) | AU2016264649B2 (en) |
CA (1) | CA2986486C (en) |
IL (1) | IL255785B (en) |
RU (1) | RU2703952C2 (en) |
TW (4) | TWI614264B (en) |
WO (1) | WO2016184426A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160339115A1 (en) * | 2015-05-20 | 2016-11-24 | Immunwork Inc. | Molecular constructs with targeting and effector moieties for treating central nervous system diseases |
US10675358B2 (en) | 2016-07-07 | 2020-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
US11312786B2 (en) * | 2017-07-20 | 2022-04-26 | Aptevo Research And Development Llc | Oncofetal antigen binding proteins and related compositions and methods |
US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI632160B (en) * | 2015-01-16 | 2018-08-11 | 中央研究院 | Molecular constructs with targeting and effector moieties |
US9623118B2 (en) * | 2015-09-01 | 2017-04-18 | Immunwork Inc. | Multi-arm linker constructs for treating pathological blood clots |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
RU2752671C2 (en) * | 2017-03-16 | 2021-07-29 | Иммунворк Инк. | Linker links and molecular structures containing them |
CN111372600A (en) * | 2017-03-24 | 2020-07-03 | 奥菲斯生物科学公司 | PantId for treatment of autoimmune disease |
CN117018216A (en) * | 2017-09-19 | 2023-11-10 | 免疫功坊股份有限公司 | Drug molecules with better binding affinity to albumin |
CA3089717A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against respiratory syncytial virus |
CN113493517B (en) * | 2020-04-02 | 2023-05-02 | 重庆精准生物技术有限公司 | Bispecific single chain antibody, chimeric antigen receptor constructed by same and application thereof |
EP4146280A1 (en) * | 2020-05-08 | 2023-03-15 | Mpeg LA, L.l.c. | Linker compounds |
EP3971576A1 (en) | 2020-09-21 | 2022-03-23 | Instrumentation Laboratory Company | Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample |
CN114874332B (en) * | 2022-03-30 | 2023-01-10 | 呈诺再生医学科技(珠海横琴新区)有限公司 | Use of modified RNF112 as a medicament for the treatment of ALS |
CN117510828A (en) * | 2022-07-28 | 2024-02-06 | 厦门赛诺邦格生物科技股份有限公司 | Tri-arm polyethylene glycol derivative containing amino acid residue |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858728A (en) | 1991-03-13 | 1999-01-12 | Common Services Agency | Monoclonal antibody against LPS core |
US5432260A (en) * | 1991-05-03 | 1995-07-11 | Washington University | High affinity mannose receptor ligands |
AU6015301A (en) * | 2000-03-24 | 2001-10-03 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
JP2005518343A (en) * | 2001-08-03 | 2005-06-23 | メダレックス, インク. | Novel PGC-1 isoforms and their use to improve use-mediated immunotherapy |
US7429472B2 (en) * | 2003-01-31 | 2008-09-30 | Promega Corporation | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule |
JP2008516586A (en) | 2004-09-30 | 2008-05-22 | メダレックス インコーポレーティッド | Human monoclonal antibody against Fcγ receptor II (CD32) |
RU2318500C2 (en) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Method for on body by target delivery of biologically active substances in mitochondria, pharmaceutical composition for its realization and compound used for this aim |
CN101400698A (en) * | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | Amylin derivatives |
US20080267988A1 (en) * | 2007-04-11 | 2008-10-30 | Enteron Limited Partnership | Myelin specific IgE unencumbered by corresponding blocking antibodies as a causative factor in multiple sclerosis |
JP5539993B2 (en) * | 2008-09-23 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Nanocarriers for drug delivery |
EP3903829B1 (en) * | 2009-02-13 | 2023-05-03 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
WO2011026026A1 (en) * | 2009-08-31 | 2011-03-03 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity |
WO2011029008A2 (en) * | 2009-09-04 | 2011-03-10 | Arizona Board Of Regents Acting For And On Behalf Of Arizona State University | Synbodies to akt1 |
WO2011045668A1 (en) * | 2009-10-14 | 2011-04-21 | The Governors Of The University Of Alberta | Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof |
CA2804185C (en) * | 2010-07-12 | 2017-03-21 | Covx Technologies Ireland Limited | Multifunctional antibody conjugates |
UA117801C2 (en) | 2010-11-30 | 2018-10-10 | Дженентек, Інк. | Low affinity blood brain barrier receptor antibodies and uses therefor |
WO2013004607A1 (en) * | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
SI2890402T1 (en) * | 2012-08-31 | 2019-07-31 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
US20160017058A1 (en) * | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
CA2918077A1 (en) * | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
ES2912932T3 (en) * | 2013-07-25 | 2022-05-30 | Cytomx Therapeutics Inc | Multispecific antibodies, multispecific activatable antibodies and methods of use thereof |
EP3089996B1 (en) * | 2014-01-03 | 2021-07-28 | F. Hoffmann-La Roche AG | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
AU2014381795B2 (en) * | 2014-02-06 | 2020-09-17 | X4 Pharmaceuticals (Austria) GmbH | E. coli specific antibody sequences |
TWI632160B (en) * | 2015-01-16 | 2018-08-11 | 中央研究院 | Molecular constructs with targeting and effector moieties |
US10202455B2 (en) * | 2015-05-20 | 2019-02-12 | Immunwork Inc. | Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod |
-
2016
- 2016-05-20 US US15/159,834 patent/US10202455B2/en active Active
- 2016-05-20 JP JP2018512473A patent/JP6602958B2/en active Active
- 2016-05-20 AU AU2016264649A patent/AU2016264649B2/en active Active
- 2016-05-20 TW TW105115672A patent/TWI614264B/en active
- 2016-05-20 EP EP16795913.9A patent/EP3297670A4/en active Pending
- 2016-05-20 TW TW105115671A patent/TWI614023B/en active
- 2016-05-20 US US15/159,829 patent/US9988454B2/en active Active
- 2016-05-20 CN CN201680029187.5A patent/CN107847588B/en active Active
- 2016-05-20 US US15/159,863 patent/US20160340427A1/en not_active Abandoned
- 2016-05-20 TW TW105115691A patent/TWI614030B/en active
- 2016-05-20 US US15/159,862 patent/US20160340435A1/en not_active Abandoned
- 2016-05-20 RU RU2017144294A patent/RU2703952C2/en active
- 2016-05-20 US US15/159,831 patent/US9994638B2/en active Active
- 2016-05-20 US US15/159,839 patent/US10442861B2/en active Active
- 2016-05-20 TW TW105115669A patent/TW201706312A/en unknown
- 2016-05-20 US US15/159,828 patent/US9975951B2/en active Active
- 2016-05-20 CA CA2986486A patent/CA2986486C/en active Active
- 2016-05-20 WO PCT/CN2016/082785 patent/WO2016184426A1/en active Application Filing
-
2017
- 2017-11-20 IL IL255785A patent/IL255785B/en unknown
Non-Patent Citations (7)
Title |
---|
Blight Nat. Neurosci. 2002. 5: 1051-4 * |
Bowie et al. Science, 1990, 247:1306-1310. * |
Burgess et al. J of Cell Bio. 1990, 111:2129-2138 * |
Hoke et al. Nat. Clin. Pract. Neurol. 2006: 448-454 * |
Pawson et al. 2003, Science 300:445-452 * |
Schmidt et al. Annu. Rev. Biomed. Eng. 2003. 5: 293-347 * |
't Hart et al. Curr. Opin. Neurol. 2003. 16: 375-383. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160339115A1 (en) * | 2015-05-20 | 2016-11-24 | Immunwork Inc. | Molecular constructs with targeting and effector moieties for treating central nervous system diseases |
US10202455B2 (en) * | 2015-05-20 | 2019-02-12 | Immunwork Inc. | Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod |
US10675358B2 (en) | 2016-07-07 | 2020-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
US11547761B1 (en) | 2016-07-07 | 2023-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
US11312786B2 (en) * | 2017-07-20 | 2022-04-26 | Aptevo Research And Development Llc | Oncofetal antigen binding proteins and related compositions and methods |
US11725060B2 (en) | 2017-07-20 | 2023-08-15 | Aptevo Reserch and Development LLC | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods |
US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160340435A1 (en) | Molecular constructs for treating central nervous system diseases | |
TWI769982B (en) | Anti-human transferrin receptor antibody that passes through blood-brain barrier | |
US20230242668A1 (en) | Heavy chain antibodies binding to psma | |
US9409950B2 (en) | Linker peptides and polypeptides comprising same | |
US11186639B2 (en) | Multispecific heavy chain antibodies with modified heavy chain constant regions | |
JP4857396B1 (en) | Fusion protein | |
US20180055946A1 (en) | Versatile peptide-based multi-arm linkers for constructing pharmaceutical molecules | |
JP2005509595A (en) | Binding agent with differential activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IMMUNWORK INC., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHANG, TSE-WEN;CHU, HSING-MAO;TIAN, WEI-TING;REEL/FRAME:038709/0402 Effective date: 20160519 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |